Evidence suggesting creatine as a new central neurotransmitter: presence in synaptic vesicles, release upon stimulation, effects on cortical neurons and uptake into synaptosomes and synaptic vesicles

Xiling Bian,[1,#] Jiemin Zhu,[1,#] Xiaobo Jia,[1,2,#] Wenjun Liang,[1,] Zhiqing Li[1],Sihan Yu,[1] and Yi Rao [1,*]

[1]Laboratory of Neurochemical Biology, PKU-IDG/McGovern Institute for Brain Research, Peking-Tsinghua Center for Life Sciences, School of Life Sciences, Department of Chemical Biology, College of Chemistry and Chemical Engineering, School of Pharmaceutical Sciences, Peking University, Beijing 100871; Chinese Institute for Brain Research (CIBR), Beijing; Capital Medical University; Changping Laboratory, Yard 28, Science Park Road, Changping District, Beijing, China.

[2]Research Unit of Medical Neurobiology, Chinese Academy of Medical Sciences

[#]These authors are co-first authors.

*Corresponding author (email: yrao@pku.edu.cn)

It has never been easy to discover a new neurotransmitter, especially one in the central nervous system (CNS). We have been searching for new neurotransmitters for 12 years. We detected creatine (Cr) in synaptic vesicles (SVs), at a level lower than glutamate (Glu) and gamma-aminobutyric acid (GABA) but higher than acetylcholine (ACh) and 5-hydroxytryptamine (5-HT). SV Cr was reduced in mice lacking either arginine:glycine amidinotransferase (AGAT, a Cr synthetase) or SLC6A8, a Cr transporter with mutations among the most common causes of intellectual disability (ID) in men. Calcium-dependent release of Cr was detected after stimulation in brain slices. Cr release was reduced in SLC6A8 and AGAT mutants. Cr inhibited neocortical pyramidal neurons. SLC6A8 was necessary for Cr uptake into synaptosomes. Cr was found by us to be taken up into SVs in an ATP dependent manner. Thus, our biochemical, chemical, genetic and electrophysiological results suggest Cr as a neurotransmitter, illustrate a novel approach to discover neurotransmitters and provide a new basis for ID pathogenesis.

Neural signaling depends on chemical transmission between neurons and their target cells [1-6]. Neurotransmission depends on chemicals such as neurotransmitters, neuromodulators and neuropeptides. Decades of work, sometimes with convoluted paths, were involved before a molecule was established as a classic neurotransmitter [7]. Initial hints about cholinergic signaling were obtained in the 1800s [8-11]. Choline [12,13] and acetylcholine (ACh) [14] were discovered decades before their pharmacological effects were found around the turn of 20th century [15-17]. Henry Dale and colleagues realized similarities of ACh and parasympathetic stimulation [5,18] but it was not until 1929 when ACh was detected in the body [19] and 1934 when ACh was proven a neurotransmitter in the peripheral nervous system (PNS) [20-22]. It took nearly 100 years from the finding of the effects of supradrenal gland damage [23] or removal [24], the observation of an activity in the supradrenal gland [25], the isolation of an inactive derivative [26-29], and the successful isolation of adrenaline [30-32], the notice of similarities between adrenaline and sympathetic stimulation [3,4,33-35], to the mid-1940s when Ulf von Euler proved that noradrenaline (NA) was the neurotransmitter of the sympathetic nerves [36-38]. While it is not easy to establish a molecule as a neurotransmitter in the PNS, it is even harder to establish a central nervous system (CNS) neurotransmitter. Three decades elapsed between the time when ACh was proven to be a PNS neurotransmitter and the time when it was established as a CNS neurotransmitter [39-41] and two decades between NA as a peripheral transmitter and a central transmitter [42,43].

If a neurotransmitter acts only in the CNS, but not in the PNS, it is much more difficult to discover or to prove. Most neurotransmitters were discovered for their

effects on peripheral tissues, with muscle contraction or relaxation as a major readout. Glutamate (Glu) [44-47] and gamma-aminobutyric acid (GABA) [46,48-51] were discovered partly because of their peripheral effects and partly because of their effects on spinal neurons. There is no reason for central neurotransmitters to also act peripherally, but relatively little efforts have been reported to find small molecule neurotransmitters acting only on CNS neurons with no peripheral bioassays available. Premature assumptions and technical difficulties are among the major reasons why the hunt for neurotransmitters has not been a highly active area of research over the last three decades.

Are there more neurotransmitters and how can they be discovered? Classic neurotransmitters are stored in synaptic vesicles (SVs) [52-60]. They are released upon electric stimulation before being degraded enzymatically or taken up into the presynaptic terminal by cytoplasmic transporters and into SVs by vesicular transporters [61-66]. Most of the major textbooks list either 3 [67-69] or 4 [70-72] criteria of a neurotransmitter: presence in presynaptic neurons, release upon stimulation, action on postsynaptic neurons, mechanism of removal. Some molecules commonly accepted as neurotransmitters still do not meet all the criteria listed in different textbooks, but they nonetheless play important functional roles in the CNS and their defects cause human diseases. Over time, different small molecules have been proposed to function as neurotransmitters (e.g., 46,73), but none satisfies all the criteria. Robust and reliable detection of the candidate molecule in SVs is often, though not always, the problem (cf. 74).

Beginning in 2011, we have been actively searching for new neurotransmitters in the mammalian brain. We have tried different approaches, including searching for neuroactive substances in the cerebral spinal fluid (CSF) and following transporters potentially localized in the SVs. One approach that we have now taken to fruition is the purification of the SVs from mouse brains coupled with chemical analysis of their contents. We have found known transmitters such as Glu, GABA, ACh, and 5-hydroxytryptamine (5-HT). But more importantly, we have reproducibly detected creatine (Cr) in SVs.

Cr was discovered in 1832 by Michel-Eugène Chevreul [75,76] and has long been considered as an energy buffer in the muscle and the brain [77-79]. Half of Cr in a mammalian animal is thought to come from diet and the rest from endogenous synthesis [80]. Most of the Cr is present in the muscle but it is also present in the brain. Although most of the endogenous Cr is synthesized in the kidney, the pancreas and the liver [77,81], Cr is also synthesized in the brain [80,82,83].

Solute carriers (SLC) contribute to both cytoplasmic and vesicular transporters. With 19 members in humans, family 6 (SLC6) are secondary active transporters relying on electrochemical Na^+ or H^+ gradients [84-89]. SLC6 is also known as the neurotransmitter transporter (NTT) family because some members transport neurotransmitters such as GABA (by SLC6A1 or GABA transporter 1, GAT1; SLC6A13 or GAT2; SLC6A11 or GAT3) [90-93], NA (by SLC6A2 or NA transporter, NET) [65], dopamine (by SLC6A3 or DAT) [94-96], 5-HT (by SLC6A4 or serotonin transporter, SERT) [66,97], and glycine (by SLC6A9, or GlyT1; SLC6A5 or GlyT2) [90,98,99].

Cr is transported by SLC6A8 (also known as CrT, CT1 or CRCT) [100-106]. In addition to peripheral organs and tissues, SLC6A8 is also expressed in the nervous system where it is mainly in neurons [82,104,107-109]. SLC6A8 protein could be found on the plasma membrane of neurons [109-111].

The functional significance of SLC6A8 in the brain is supported by symptoms of humans defective in SLC6A8. Mutations in SLC6A8 were found in human patients with intellectual disability (ID), delayed language development, epileptic seizures and autistic-like behaviors [112,113]. They are collectedly known as Cr transporter deficiency (CTD), with ID as the hallmark. Particular vulnerability of language development has been observed in some SLC6A8 mutations which had mild ID but severe language delay [114]. CTD contributes to approximately 1 to 2.1% of X-linked mental retardation [115-123]. While CTD is highly prevalent in ID males, it is also present in females, with an estimated carrier frequency of 0.024% [124].

SLC6A8 knockout mice [125-127] showed typical symptoms of human CTD patients with early and progressive impairment in learning and memory. Mice with brain- and neuronal-specific knockout of SLC6A8 showed deficits in learning and memory without changes in locomotion caused by peripheral involvement of SLC6A8 [128,129]. Deletion of SLC6A8 from dopaminergic neurons in the brain caused hyperactivity [130]. These results demonstrate that SLC6A8 is functionally important in neurons.

Cr deficiency syndromes (CDS) are inborn errors of Cr metabolism, which can result from defects in one of the three genes: guanidinoacetate methyltransferase (GAMT) [131], arginine-glycine amidinotransferase (AGAT) [132,133], and SLC6A8 [112].

That they all show brain disorders indicates the functional importance of Cr in the brain [134-137].

Here we first biochemically purified SVs from the mouse brain and discovered the presence of Cr, as well as classic neurotransmitters Glu and GABA, ACh and 5-HT, in SVs. We then detected calcium (Ca^{2+}) dependent releases of Cr, Glu and GABA but not ACh and 5-HT when neurons were depolarized by increased extracellular concentrations of potassium (K^{+}). Both the level of Cr in SVs and that of Cr released upon stimulation were decreased significantly when either the gene for SLC6A8 or the gene for AGAT were eliminated genetically. When Cr was applied to slices from the neocortex, the activities of pyramidal neurons were inhibited. Furthermore, we confirmed that Cr was taken up by synaptosomes and found that Cr uptake was significantly reduced when the SLC6A8 gene was deleted. Finally, we found that Cr was transported into SVs. Thus, multidisciplinary approaches with biochemistry, genetics and electrophysiology have obtained results consistent with the possibility of Cr as a neurotransmitter.

Detection of Cr in SVs from the mouse brain

To search for new neurotransmitters, we tried several approaches. For example, we used Ca^{2+} imaging to detect neuroactive substances in the cerebrospinal fluid (CSF), but it was difficult to rule out existing neurotransmitters and select responses from potentially new neurotransmitters. We also transfected cDNAs for all human SLCs into dissociated cultures of primary neurons from the mouse brain and found that

more than 50 out of all SLCs could be localized in SVs. However, when we used CRISPR-CAS9 to tag some of the candidate SLCs in mice, some of them were found to be expressed outside the CNS, indicating that, while ectopic expression of these candidate SLCs could be localized on SVs, the endogenous counterparts were not localized on SVs.

Here we report our approach using the purification of SVs as the first step (Extended Data Fig. 1**a**) [138-145]. Synaptophysin (Syp) is a specific marker for SVs [146-149] and an anti-Syp antibody was used to immunoisolate SVs [143,144,150-152]. Visualization by electronic microscopy (EM) (Extended Data Fig. 1**b**, left panel) showed that the purified vesicles were homogenous, with an average diameter of 40.44 ± 0.26 nm (n=596 particles) (Extended Data Fig. 1**b**, right panel), consistent with previous descriptions of SVs [153,154].

Immunoblot analysis with twenty markers of subcellular organelles of neurons and one marker for glia (Extended Data Fig. 1**c**) indicate that our purifications were highly effective, with SV markers detected after purification with the anti-Syp antibody, but not that with the control immunoglobulin G (IgG). SV proteins included Syp [146-149], synaptotagmin (Syt1) [155], synatobrevin2 (Syb2) [156,157], SV2A [158], H^+-ATPase [159], and vesicular neurotransmitter transporters for glutamate (VGLUT1, VGLUT2) [160] and GABA (VGAT) [161]. Immunoisolation by the anti-Syp antibody did not bring down markers for the synaptic membrane (with SNAP23 as a marker) [162-164], postsynaptic components (with PSD95 and GluN1 as markers) [165,166], the Golgi apparatus (with GM130 and Golgin 97 as markers) [167,168], early endosome (with early

endosome-associated 1, EEA1, as a marker) [169], the lysosome (with LC3B and cathepsinB as markers), the cytoplasma (with glyceraldehyde-3-phophate dehydrogenase or GAPDH as a marker), mitochondria (with voltage-dependent anion channel or VDAC, as a marker), cytoplasmic membrane (with calcium voltage-gated channel subunit alpha 1 or CACNA1A as a marker), axonal membrane (with glucose transporter type 4 or GluT4 as a marker) and glia membrane (with myelin basic protein or MBP as a marker). These results indicated that the SVs we obtained were of high integrity and purity.

To detect and quantify small molecules as candidate transmitters present in the purified SVs, capillary electrophoresis-mass spectrometry (CE-MS) was optimized and utilized (Fig. 1**a**, Extended Data Fig. 1**a**) [151,170]. We found that the levels of classical neurotransmitters such as Glu, GABA, ACh and 5-HT were significantly higher in SVs pulled down by the anti-Syp antibody than those in lysates pulled down by the control IgG (Fig. 1 **a**-**e**). Consistent with previous reports [144,151], significant enrichment of neurotransmitters was observed only from SVs immunoisolated at near 0 ºC, but not at the room temperature (RT) (Fig. 1 **a**-**e**). By contrast, another small molecule, alanine (Fig. 1**g**), was not elevated in SVs as compared to the control.

The amount of Glu was 171.1 ± 5.4 pmol/μg anti-Syp antibody (n=10, Fig. 1**b**), approximately 10 times that of GABA (17.81 ± 1.47 pmol/μg anti-Syp antibody, Fig. 1**c**). The amount of ACh was 1.29 ± 0.10 pmol/μg anti-Syp antibody (Fig. 1**d**), approximately 0.072 that of GABA. The amount of 5-HT was 0.096 ± 0.017 pmol/μg

anti-Syp antibody (Fig. 1**e**). Thus, our purification and detection methods were highly reliable and sensitive enough to detect established neurotransmitters.

Under the same conditions, we also detected Cr in SVs (Fig. 1**a** and 1**f**). Amount of Cr in the SVs was found to be 3.43 ± 0.40 pmol/μg anti-Syp antibody (Fig. 1**f**), which was approximately 2% of Glu, 19% of GABA, 266% of ACh and 3573% of 5-HT. It is unlikely that these could be attributable to different levels for different neurotransmitters in each SV, but more likely attributable to the relative abundance of SVs containing different neurotransmitters. 85% to 90% neurons in the mouse brain were glutamatergic while 10%-15% were GABAergic [171-173], which can explain our detection of Glu as approximately 10 times that of GABA (Fig. 1**b**, 1**c**). Similarly, cholinergic neurons (5.67×10^5) [174] represented 0.81% of total number of neurons (approximately 70 million) in the mouse brain [175], serotonergic neurons (approximately 26,000) for 0.037% of total neurons [175,176]. Assuming that the content of each neurotransmitter in a single SV is similar, extrapolation from the above data would suggest that approximately 1.3% to 2.15% of neurons in the mouse brain are creatinergic.

To distinguish whether small molecules co-purified with SVs were in the SVs [143,144], or that they were just associated with the outside of SVs[154], we tested the dependence of the presence of these molecules in the SVs on temperature and on the electrochemical gradient of H^+. Cr was significantly reduced in SVs purified at the room temperature as compared to that immunoisolated at near 0 ºC (Fig. 1**f**), supporting the presence of Cr inside, instead of outside, SVs.

Classical neurotransmitters are stored in SVs with an acidic environment inside (pH of 5.6 ~ 6.4) [177-179]. To further verify the storage of Cr in SVs and examine the role of H^+ electrochemical gradient, we applied pharmacological inhibitors during purification [74,180]. The proton ionophore FCCP (carbonyl cyanide-4-(tri-fluoromethoxy) phenylhydrazone) was used to dissipate H^+ electrochemical gradient [180, 181]. FCCP significantly reduced the amount of Cr as well as classical neurotransmitters in SVs (Extended Data Fig. 2 **a**-**e**). The extent of FCCP induced reduction was correlated with the value of pKa or PI (isoelectric point) for different molecule: 5-HT (with pKa predicted to 10 and 9.31, Extended Data Fig. 2**e**) > Cr (PI of ~7.94, Extended Data Fig. 2**a**) > GABA (PI of 7.33, Extended Data Fig. 2**c**) > Glu (PI of 3.22, Extended Data Fig. 2 b). Nigericin, a K^+/H^+ exchanger which dissipates ΔpH[180,181], also reduced the amount of Cr and classical neurotransmitters in SVs (Extended Data Fig. 2 **a**-**e**). Furthermore, in the presence of FCCP or nigerin, SV Cr was reduced to a level comparable to that pulled down by control IgG (Extended Data Fig. 2**a**), demonstrating the storage of Cr in SVs was dependent on H^+ gradient. As a control, the non-neurotransmitter molecule alanine in SVs was not changed by the inhibitors (Extended Data Fig. 2**f**).

Reduction of SV Cr in mouse mutants lacking slc6a8

SLC6A8, located on the X chromosome, encodes a transporter for Cr and its loss of function (LOF) mutations caused behavioral deficits in humans [112,113] and mice [125-130]. To investigate whether SLC6A8 affects Cr in SVs, we generated slc6a8 knockout (KO)

mice. Exon 1 of the SLC6A8 gene was partially replaced with CreERT2-WPRE-polyA by CRISPR/Cas9 (Fig. 2**a**). Examination by reverse polymerase chain reaction (RT-PCR) (Extended Data Fig. 3 **a** and **b**) and quantitative real-time reverse PCR (qPCR, Extended Data Fig. 3 **c** and **d**) showed that SLC6A8 mRNA was not detected in either male or female mutants, and significantly reduced in female heterozygous (Slc6a8$^{+/-}$). Consistent with previous reports, the body weights of SLC6A8 KO mice were reduced (Extended Data Fig. 4 **b** and **d**) [125,182,183]. Brain weight was not significantly different between SLC6A8 KO mice and WT mice (Extended Data Fig. 4**a** and **c**).

When we examined the contents of SVs isolated by the anti-Syp antibody vs the control IgG, significant reduction was only observed for Cr, but not classical neurotransmitters (Fig. 2 **b**-**h**, Extended Data Fig. 5 **a**-**e**). While Cr pulled down by IgG was not significantly different between SLC6A8$^{-/Y}$ and SLC6A8$^{+/Y}$ mice, SV Cr purified by the anti-Syp antibody from SLC6A8$^{-/Y}$ was reduced to approximately 1/3 that of the WT (SLC6A8$^{+/Y}$) littermates (n =14, Fig. 2 **b** and **c**). Compared to the IgG control, Cr in SVs was enriched in WT mice, but not in SLC6A8$^{-/Y}$ mice (Fig. 2 **b** and **c**). In both SLC6A8$^{-/Y}$ and SLC6A8$^{+/Y}$ mice, classical neurotransmitters in SVs were all enriched as compared to IgG controls (Fig. 2**c**-**g**, Extended Data Fig. 5**a**-**d**). The amounts of Glu (Fig. 2**d** and Extended Data Fig. 5**a**), GABA (Fig. 2**e** and Extended Data Fig. 5**b**), ACh (Fig. 2**f** and Extended Data Fig. 5**c**) and 5-HT (Fig. 2**g** and Extended Data Fig. 5**d**) in SVs were not different between SLC6A8$^{-/Y}$ and SLC6A8$^{+/Y}$

mice. Molecules not enriched in SVs from WT mice, such as alanine, was also unaffected by SLC6A8 KO (Fig. 2**h** and Extended Data Fig. 5**e**).

It is unlikely that the specific reduction of Cr in SVs from SLC6A8 KO mice was due to technical artifacts. First, the possibility of less SVs obtained from SLC6A8 KO mice were precluded by immunoblot analysis, as assessed by SV markers Syp, Syt and H^+-ATPase (Extended Data Fig. 6**a**). Second, data collected by high resolution MS (Q Exactive HF-X, Thermoscientific) also revealed selective decrease of SV Cr (m/z=132.0576) from SLC6A8 KO mice (Extended Data Fig. 6 **b**-**g**), as quantified by the peak area. Peak areas for Glu (Extended Data Fig. 6**b**, m/z=148.0604), GABA (Extended Data Fig. 6**c**, m/z=104.0712), ACh (Extended Data Fig. 6**d**, m/z = 146.1178) and alanine (Ala, Extended Data Fig. 6**e**, m/z=90.055) were not significantly different between SVs immmunoisolated with the anti-Syp antibody and control IgG from WT and Slc6a8 KO mice. However, peak areas (Extended Data Fig. 5**g**) and amplitude of Cr (Extended Data Fig. 5**f**) signal were significantly increased in SVs from WT mice (anti-Syp antibody vs IgG), but not that from SLC6A8 KO mice.

Reduction of SV Cr in mouse mutants lacking AGAT

AGAT is the enzyme catalyzing the first step in Cr synthesis [82,184] and its absence also led to Cr deficiency in the human brain and mental retardation [132,133].

To investigate requirement of AGAT for SV Cr, we utilized AGAT 'knockout-first' mice (Fig. 6**a**) [185]. The targeting cassette containing Frt (Flip recombination sites)-flanked EnS2A, an IRES::lacZ trapping cassette and a floxed *neo* cassette were

inserted downstream of exon 2 to interfere with normal splicing of AGAT pre-mRNA. Examination by RT-PCR (Extended Data Fig.7**a**) and quantitative rtPCR (Extended Data Fig. 7**b**) showed reduction of AGAT mRNA in $AGAT^{+/-}$ mice and absence of AGAT mRNA in $AGAT^{-/-}$ mice. Body weight (Extended Data Fig. 8**b**), but not brain weight (Extended Data Fig. 8**a**), of $AGAT^{-/-}$ mice were lower than both $AGAT^{+/+}$ and $AGAT^{+/-}$ mice, which were similar to SLC6A8 KO mice.

Immunoblot analysis showed SVs purified from the brains were not significantly different among $AGAT^{+/+}$, $AGAT^{+/-}$ and $AGAT^{-/-}$ mice (Extended Data Fig. 9 **a-d**), as supported by quantitative analysis of Syp, Syt and H^+-ATPase (n=20).

We analyzed small molecules present in SVs from $AGAT^{+/+}$, $AGAT^{+/-}$ and $AGAT^{-/-}$ mice. Cr was significantly enriched in SVs from all three genotypes as compared to the IgG control (Fig. 3 **a** and **b**). However, the level of Cr from $AGAT^{-/-}$ mice was significantly lower than those from $AGAT^{+/+}$ and $AGAT^{+/-}$ mice (n=10, Fig. 3 **a** and **b**).

Glu (Fig. 3**c**), ACh (Fig. 3**e**) and 5-HT (Fig. 3**f**) were all enriched in SVs (as compared to IgG controls), and not significantly different among $AGAT^{+/+}$, $AGAT^{+/-}$ and $AGAT^{-/-}$ mice. GABA in SVs from $AGAT^{-/-}$ mice was also decreased from $AGAT^{+/+}$ mice by 30%, to an extent less than that of Cr (78.4%). Alanine was not different among three genotypes of mice (n=6, Fig. 3**g**). Thus, Cr and GABA, but not other neurotransmitters, in SVs were reduced in AGAT KO mice.

Pattern of SLC6A8 expression indicated by knockin mice

We generated SLC6A8-HA knockin mice by CRISPR/Cas9. Three repeats of the hemagglutinin (HA) tag [186], the T2A sequence [187-189] and CreERT2 [190-193] were inserted in-frame at the C terminus of the SLC6A8 protein (Fig. 4**a**).

To examine the expression pattern of SLC6A8, we performed immunocytochemistry with an antibody against the HA epitope in SLC6A8-HA and WT mice. SLC6A8-HA mice showed positive signals in the olfactory bulb (Fig. 4**b**), the piriform cortex (Figs. 4 **c-f**), the somatosensory cortex (Figs. 4 **f** and **g**), the ventral posterior thalamus (Fig. 4**h**), the interpeduncular nucleus (Fig. 4**i**) and the pontine nuclei (Fig. 4**j**). In addition, moderate levels of immunoreactivity were observed in the motor cortex (Figs 4 **d-h**), the medial habenular nucleus (Fig. 4**h**), the hippocampus (Fig. 4**h**) and the cerebellum (Fig. 4**k**). These results were consistent with previous reports [109,111]. WT mice were negative for anti-HA antibody staining (Figs 4 **l** and **m**).

Ca^{2+} dependent release of Cr upon stimulation

Classical neurotransmitters are released from the SVs into the synaptic cleft in a Ca^{2+} dependent manner after stimulation. For example, high extracellular potassium (K^+) stimulated Ca^{2+} dependent release of Glu, GABA and other neurotransmitters in brain slices [194-198].

300 μm thick coronal slices of the mouse brain within 1~2 millimeters (mm) posterior to the bregma were used, because the cortex, the thalamus, the habenular nucleus and the hippocampus were positive for SLC6A8 (cf., Fig. 4**h**). We monitored the effect of K^+ stimulation by recording neurons in the slices. Immediately

after K^+ stimulation, pyramidal neurons in the CA1 region of the hippocampus were depolarized, firing a train of action potentials and reaching a large depolarization plateau in less than 1 minute (min) (Fig. 5**a**). K^+-induced depolarization persisted for several mins before returning to the baseline and being washed within 10 mins. Thus, superfusates in 1-min fraction at the time points of 1.5 min before (control) and after K^+ stimulation, and 10 mins after the wash were collected (Fig. 5**a**), and the metabolites in the superfusates were analyzed by CE-MS.

In the presence of Ca^{2+}, depolarization with elevated extracellular K^+ led to robust release of Glu and GABA in slices from WT (SLC6A8$^+$/Y) mice (Figs. 5**a** and **c**). After 10 mins wash, levels of Glu and GABA returned to the baseline (Fig. 5**b** and **c**). In the presence of Ca^{2+}, depolarization with elevated K^+ led to robust release of Cr. Extracellular Cr returned to the baseline after 10 min wash (Fig. 5**d**). For quantification, the stimulated releases of metabolites were calculated by subtracting the basal levels from the total releases in response to K^+ stimulation. In the presence of Ca^{2+}, K^+ stimulation induced the efflux of Glu, GABA and Cr at 0.46, 0.33 and 0.086 nmol/min, respectively (n=7 per group) (Figs. 5 **b**, **c**, **d**). From the detection limits of ACh and 5-HT in our system, we inferred that the efflux rate for ACh was lower than 0.001 nmol/min and that for 5-HT lower than 0.003 nmol/min. The efflux rate for Cr in brain slices is lower than those of Glu and GABA, but higher than those for ACh and 5-HT.

Ca^{2+} dependence of transmitter release was examined by comparing responses to ACSF without Ca^{2+} or elevated K^+ (supplemented with 1 mM EGTA), elevated

extracullular K^+ in the absence of Ca^{2+} (supplemented with 1 mM EGTA), or K^+ in presence of 2.5 mM Ca^{2+} (Fig. 5 **e**-**g**, n=5 per group). In the absence of Ca^{2+}, elevated K^+ stimulated the release of a small but significant amount of Glu and GABA, with efflux rates at 0.056 nmol/min and 0.066 respectively (Figs. 5**e**, **f**). In the presence of 2.5 mM Ca^{2+}, elevated K^+ further augmented the release of Glu and GABA by 5 to 6 times, confirming previously reported Ca^{2+} dependent release of neurotransmitters in response to depolarization [194,196].

Cr was also released both in a Ca^{2+} dependent and a Ca^{2+} independent manner (Fig. 5**g**). More Cr was released in response to K^+ stimulation in the presence of 2.5 mM Ca^{2+} than that in the absence of Ca^{2+}. These results demonstrate Ca^{2+} dependent release of Cr upon stimulation.

Cr release reduced in SLC6A8 and AGAT mutant mice

We examined whether SLC6A8 KO affected K^+-induced release of Cr. While Glu and GABA were released in slices from SLC6A8 KO (SLC6A8$^-$/Y) mice at levels not significantly different from those of WT mice (Figs. 5 **b**, **c**), release of Cr in response to K^+ stimulation was significantly reduced in SLC6A8$^{-/Y}$ mice as compared to SLC6A8$^{+/Y}$ mice (Fig. 5**d**). The basal level of Cr in SLC6A8 KO mice was lower than that of WT mice. In addition, K^+ stimulation induced release of Cr persisted to some extent even after 10 mins of washout (Fig. 5**d**), possibly due to the inability of presynaptic terminals in SLC6A8 KO mice to reuptake Cr in the synaptic cleft (Fig. 8).

Experiments with slices from brains of SLC6A8 KO (SLC6A8$^-$/Y) mice showed that Ca^{2+} dependent release of either Glu or GABA was not affected by the genotype of SLC6A8 (Figs. 5**e**, **f**). By contrast, Ca^{2+} dependent release of Cr was abolished in SLC6A8$^-$/Y slices. Interestingly, Ca^{2+} independent release of Cr was significantly reduced, but not abolished in SLC6A8$^-$/Y slices. In the absence of Ca^{2+}, the basal level of Cr was not changed in SLC6A8 KO mice. Taken together, these results indicate that there is Ca^{2+} dependent release of Cr upon stimulation and that SLC6A8 is required specifically for Ca^{2+} dependent release of Cr, but not for Ca^{2+} dependent release of other neurotransmitters such as Glu and GABA, or for Ca^{2+} independent release of Cr.

Knockout of AGAT (Fig. 6**a**) selectively reduced K^+ evoked release of Cr, but not those of Glu or GABA (n=5 per group, Figs. 6**b**, **c**, **d**). Although K^+ stimulation still elicited Cr release from brain slices of AGAT$^{+/-}$ mice, the efflux rate in AGAT$^{-/-}$ mice was reduced to less than 10% that in AGAT$^{+/+}$ mice and 20% that in AGAT$^{+/-}$ mice. Thus, there is a strong AGAT dependent component in K^+ induced release of Cr.

Cr inhibition of neocortical neurons

Our own data (Fig. 4**h**) and previous reports [109,111] have shown SLC6A8 in the neocortex, with dense SLA6A8-HA immunoreactive fibers in layer 4 (Extended Data Fig. 10**a**) [199,200]. Layer 5 neurons in the somatosensory cortex have been reported to express SLC6A8 previously [109,111]. To investigate electrophysiological effects of Cr,

we performed whole cell patch clamp recordings from the pyramidal neurons in layer 4/5 of the somatosensory cortex (Figs. 7 **a**, **b**, Extended Data Fig. 10).

Medium-sized pyramidal neurons (Fig. 7**b**) with a membrane capacitance (Cm) of 114.96 ± 3.92 pF (n=51, Extended Data Fig. 11**a**) were recorded. These neurons exhibited regular firing patterns [201,202] in response to depolarization current injection (Fig. 7**d** and Extended Data Fig. 11**a**) with moderate maximal evoked spiking frequencies of 10-30 spikes per 500 milliseconds (ms) (Fig. 7 **e**-**g**), increasing of inter-spike intervals during depolarizing steps (Fig. 7**d** and Extended Data Fig. 11**a**), high action potential amplitude (81.64 ± 1.06 mV, Extended Data Fig. 12**e**) and large spike half-width (1.12 ± 0.031 ms, Extended Fig. 12**f**).

Cr was bath applied only after the evoked firing pattern reached a steady state. Of the 51 neurons, 16 were inhibited by 100 μM creatine (Fig. 7 **b**-**f**). Fewer spikes were evoked in Cr responsive neurons in response to depolarizing current injections during Cr application (25 pA step, 500 ms) (Fig. 7 **d**-**f**). The inhibitory effect of Cr was reversible (Fig. 7 **d**-**f**), typically observed in 2 to 8 min following Cr application, and disappeared after 10 to 25 min washout. This could be repeated by a second application of Cr. The rheobase, defined as the minimal electrical current necessary to elicit an action potential, was increased during bath application of Cr (Fig. 7**h**). The inhibitory effect was most obvious at near spike threshold. When a neuron was depolarized with a current of 50 pA above rheobase, the number of evoked spikes was decreased dramatically during Cr application (Fig. 7**i**). Cr also mildly inhibited the input resistance (Fig. 7**j**), slightly hyperpolarized resting membrane potential (Extended Data

Fig. 12**c**) or reduced amplitude of afterhyperploarization (AHP) followed by the first evoked action potential (Extended Data Fig. 12**g**). The spike threshold (Extended Data Fig. 12**d**), amplitude (Extended Data Fig. 12**e**) and half width (Extended Data Fig. 12**f**) were not changed by Cr.

The remaining 35 neurons were not responsive to Cr (Figs. 7 **c** and **g**, Extended Data Fig. 11). Cr did not change electrical parameters tested, including evoked firing rates (Fig. 7**g**, Extended Data Fig. 11 **a**, **b** and **d**), rheobase (Extended Data Fig. 11**c**), resting membrane potential (Extended Data Fig. 12**c**), spike threshold amplitude (Extended Data Fig. 12**e**) and half width (Extended Data Fig. 12**f**). In addition, electrical properties of responsive neurons and unresponsive neurons were not significantly different. With the limited number of neurons recorded, the ratio of responsive neurons appeared higher in layer 4 or border of layer4/5, than the deeper layer in layer 5 (Extended Data Fig. 10).

SLC6A8 dependent uptake of Cr into the synaptosomes

Along with enzymatic degradation, re-uptake by transporters serves as an important way to remove neurotransmitters released into the synaptic cleft. As synaptosomes contain the apparatus for neurotransmission, they are often used for studying uptake of neurotransmitters [203].

To investigate whether Cr uptake into synaptosomes required SLC6A8, we first examined whether SLC6A8 was present in synaptosomes. Using Slc6a8-HA knockin mice and an anti-HA antibody, we found that SLC6A8-HA was present and enriched in

crude synaptosomal fraction (P2 fraction in Fig. 8**a**, enrichment score: P2/H = 1.76 ± 0.15, n = 4) and synaptosomal fraction prepared using a discontinuous Ficoll gradient (Sy and 4-Sy fractions in Fig. 8**a**, enrichment score: Sy/H = 2.02 ±0.14, n = 4). The integrity of synaptosomes was confirmed by multiple markers of the synaptosomes [203], including the presynaptic membrane marker SNAP25 [204] and the SV marker Syp (synaptophysin Syp) [146-149] in presynaptic terminals, the postsynaptic density marker PSD95 [165,166] and the postsynaptic membrane protein GluN1 [205], the synaptic membrane protein SNAP23 [162-164], the plasma membrane marker Na^+-K^+-ATPase [206-208], and the mitochondria marker VDAC [203]. These were all enriched in our synaptosomal preparations. The cytosol marker GAPDH was also present in synaptosomes, whereas the oligodendrocyte marker MBP was nearly absent, suggesting myelin pollution was largely avoided [203].

We have also used EM to confirm the quality of our synaptosome preparations. As reported previously [203,209], synaptosomes were composed of membrane bounded structures (Sy in Fig. 8**b**) filled with synaptic vesicles (SV in Fig. 8**b**), sometimes with a segment of postsynaptic membrane along with the postsynaptic density (PSD in Fig. 8**b**) and mitochondria (Mt in Fig. 8**b**). The sizes of synaptosomes from WT mice and *Slc6a8* knockout mice were similar, with areas of 0.245 ± 0.01 μm^2 (n=302 particles) and 0.247 ± 0.01 μm^2 (n=317 particles), respectively (Fig. 8**b**).

We then examined whether SLC6a8 participated in Cr uptake into the synaptosomes. A mixture of 18 μM [^{14}C]-Cr (with a total radioactivity of 0.4 μCi) and 5 μM Cr was used, and uptake at 0 ºC measured at 10 mins was the baseline [210]. Cr uptake

into synaptosomes from WT mice was stimulated approximately sevenfold at 37 ºC (Uptake, Fig. 8**c**) as compared with 0 ºC (Ctrl, Fig. 8**c**). Cr uptake into synaptosomes from SLC6a8 knockout mice was less than 3 times as compared to its control, and was decreased to approximately 1/3 of that of WT mice (Fig. 8**c**). Thus, SLC6A8 is necessary for uptake of Cr into the synaptosomes.

Cr uptake into SVs

Classical neurotransmitters were taken up in SVs in an ATP-dependent manner[144,159,181,210,211]. We examined whether Cr could be transported into SVs.

We used 10 μg anti-Syp antibody to purify SVs from mouse brains. Purified SVs were mixed with 1 mM [^{13}C]-Cr in the presence or absence of 4 mM ATP and placed at 25 □ for 10 mins to allow adequate uptake. The SV content of [^{13}C]-Cr was then examined by high-performance liquid chromatography-mass spectrometry (HPLC-MS). Significantly more [^{13}C]-Cr were taken up by SVs in the presence of ATP, with about 3.3 pmol [^{13}C]-Cr transported into SVs (0.33 pmol/μg α-Syp or transportation rate of 0.033 pmol/min, n=3, Fig. 8**d**). In the absence of ATP, less than 0.5 pmol [^{13}C]-Cr was absorbed by SVs, as inferred from the detection limits of HPLC/MS.

In summary, Cr could be transported into SVs in ATP-dependent manner. At this point, we do not know what is the transporter(s) on the SVs for Cr uptake. SLC6A8 is

only found in plasma membrane, not on SVs, and is not a candidate for Cr uptake into SVs.

DISCUSSION

At various times and by different researchers, taurine [46,212], proline [73], D-aspartic acid [213], hydrogen sulfide [214], agmatine [215], DOPA [216], estradiol [217], β-alanine [218], protons [219] have been suspected as neurotransmitters, but they do not meet all the criteria. Some of the suspected molecules can be released upon stimulation or removed by transporters. Often, they have not been reproducibly found in SVs [74].

Our discovery of Cr in SVs significantly raised the priority of testing the candidacy of Cr, and our further investigations have led to more evidence suggesting Cr as a neurotransmitter: 1) Cr is stored in SVs; 2) Ca^{++} dependent release of Cr upon stimulation has been observed; 3) both Cr storage in SVs and Cr release are reduced when either the gene for SLC6A8 or the gene for AGAT was deficient; and 4) Cr inhibits activities of pyramidal neurons in the neocortex; 5) Cr uptake into synaptosomes requires SLC6A8; 6) Cr uptake into SVs was ATP-dependent.

Of the above results, 1, 3, 4 and 6 are reported for the first time in this paper. Furthermore, we have demonstrated that detection of Cr in SVs was lower than those for Glu and GABA, but higher than those for ACh and 5-HT, placing Cr at a level in the middle of known central transmitters (Figs. 1-3). The storage of Cr in SVs is dependent on preserved H^+ gradient (Extended Data Fig. 2) and Cr can be transported into SVs (Fig. 8**d**).

There was a single previous report of Ca^{++} dependent release of [^{3}H]Cr and endogenous Cr in response to electrical stimulation [220]. We now provide evidence that Cr was released in response to extracellular K^+ stimulation (within 1-2 min) (Figs. 5-6). Furthermore, Cr release was reduced when either the Slc6A8 or AGAT gene was removed (Figs. 5-6). Although the Ca^{2+} dependent component of K^+ evoked Cr release was smaller as compared to those of Glu and GABA, it nevertheless existed and was totally abolished by Slc6A8 knockout (Fig 5). The reported electrically evoked Cr release showed more Ca^{2+} dependence [220]. Taken together, our data and previous report [220] supported a role of Cr as a neurotransmitter. Our observation of extremely low efflux rates of 5-HT or ACh may have arisen from very limited numbers of cholinergic[174] or serotoninergic neurons[176] in the sliced sections and rapid enzymatic degradation of these neurotransmitters.

Cr uptake from the extracellular space into the cells was reported twice previously, once with brain slices showing sodium dependent uptake of [^{3}H]Cr [220] and once with synaptosomes [221]. Our new results have not only replicated the synaptosome Cr uptake experiment but also shown the requirement of SLC6A8, a membrane transporter expressed in synaptosomes (Fig. 8**a**), for Cr uptake into synaptosomes. Transportation of Cr into synaptosomes by Slc6A8 may function for both the clearance of Cr from the synaptic cleft and recycling of Cr into SVs residing in neurons (Fig. 8**b**, Fig. 6**d**).

In summary, in addition to confirming and extending previous results which have stood alone for more than a decade without replication or follow-up, we have obtained entirely new results suggesting the candidacy of Cr as a neurotransmitter. We discuss

below the criteria for a neurotransmitter, Cr as a neurotransmitter, and the implications of Cr as a neurotransmitter.

Criteria of a neurotransmitter

The criteria for establishing a non-peptide small molecule as a neurotransmitter have varied from time to time and from author to author.

Some textbooks simply state that a neurotransmitter is stored presynaptically, released upon stimulation and active on postsynaptic neurons. The details of these 3 criteria can vary. For example, one textbook stipulates that "the substance must be present within the presynaptic neuron; the substance must be released in response to presynaptic depolarization, and the release must be Ca^{2+} dependent; specific receptors for the substance be present on the postsynaptic cell" [67,68]. Another states that "the molecule must be synthesized and stored in the presynaptic neuron; the molecule must be released by the presynaptic axon terminal upon stimulation; the molecule, when experimentally applied, must produce a response in the postsynaptic cell that mimics the response produced by the release of neurotransmitter from the presynaptic neuron[69].

The neuroscience textbook most widely used internationally for the last 4 decades lists 4 criteria for a neurotransmitter [70,71]: it is synthesized in the presynaptic neuron; it is present within vesicles and is released in amounts sufficient to exert a defined action on the postsynaptic neuron or effector organ; when administered exogenously in reasonable concentrations it mimics the action of the endogenous transmitter; a specific mechanism usually exists for removing the substance from the synaptic cleft. These are

similar, but not identical, to the classic textbook on neurotransmitters: a neurotransmitter "should be synthesized and released presynaptically; it must mimic the action of the endogenous compound that is release on nerve stimulation; and where possible, a pharmacological identity is required where drugs that either potentiate or block postsynaptic responses to the endogenously released agent also act identically to the suspected neurotransmitter that is administered" [222]. The pharmacological criterion is listed in another textbook [223].

Some authors note difficulties of establishing a CNS neurotransmitter. For example, a specialized neurotransmitter book states that "the candidate neurotransmitter should be present in the presynaptic terminal, be released when the presynaptic terminal is active, and when applied experimentally, induce faithful responses in the postsynaptic neuron. In practice, since central nervous system neurons continuously integrate diverse excitations and inhibitions, the last criterion is relaxed to demonstrating merely changes in such activity" [224].

Solomon Snyder, a leading scientist of classic neurotransmitters, neuropeptides and their receptors, wrote that "designating a molecule as a transmitter depends on the criteria employed, the most common of which are that the substance is synthesized in neurons, released by their terminals, mimics the effects of physiologic neurotransmission and possess a mechanism for inactivation. However, with each new candidate the rules have been modified and broadened" [225].

Evidence supporting Cr as a neurotransmitter

16 small molecules have been listed as neurotransmitters in the classic textbook [70,71]. Among them, adenosine, arachidonic acid, nitric oxide and carbon monoxide do not meet all four criteria, at the present. Cr appears to be better than these in meeting the criteria for a central neurotransmitter.

The results obtained by us in this paper have satisfied the criteria of Robinson [224] for Cr to be a CNS neurotransmitter.

Our results have also satisfied the criteria of Purves et al. [67,68], because the presence of postsynaptic receptors can be inferred by postsynaptic responses.

The four criteria of Snyder and colleagues [225] have been mostly met but the physiological neurotransmission would require more research because a specific synapse(s) would have to be defined and studied for putative creatinergic neurotransmission. This can take much longer in the CNS than the PNS.Some commonly accepted neurotransmitters have never satisfied this criterion in a strict sense. The mechanism of Cr removal criterion is met not only by the Cr uptake in brain slices [220] and in synaptosomes [221], but also by our demonstration that SLC6A8 is required for synaptosome uptake of Cr.

The four criteria of Kandel et al.[70,71] are mostly satisfied with some details requiring further research. The synthesis requirement is usually not strict because there are transmitters synthesized in some cells and transported into others where they function as transmitters. Our discovery of Cr in SVs can replace the synthesis requirement because the presence in neuronal SVs provide sufficient evidence that Cr is located in the right location to function as a neurotransmitter. The level of Cr in SVs

is higher than those of ACh and 5-HT (Figs. 1 and 2). The amount of released Cr is in the same order of magnitude as those of Glu and GABA (Figs. 5 and 6). The criterion of a specific mechanism of removal was met by Cr uptake experiments in slices [220] and in synaptosomes [221], and further strengthened by our finding of SLC6A8 involvement in synaptosome uptake of Cr (Fig. 8).

Here we report that Cr, at a concentration comparable to classical neurotransmitters, inhibits pyramidal neurons in specific regions of the mouse brain, with approximate 1/3 of pyramidal neurons responding to 100 μM Cr (Fig. 7). In previous reports, 100 μM to 2 mM of GABA[226-228], 50 μM to 2 mM of Glu [229,230], 1 to 100 μM of DA[229], 0.1-100 μM of 5-HT[231-236] were bath applied to investigate the physiological functions of neurotransmitters. Our results revealed that, when bath applied, Cr could inhibit cortical neurons at 100 μM within several minutes, with a time course similar to that of 5-HT[237 234 236] and DA [229], but significantly slower than that of Glu[230], GABA[48,227] and 5-HT[233]. We speculate that Cr may act on G-protein coupled receptors (GPCRs), rather than the fast acting ligand-gated ion channels, such as AMPA or NMDA receptors for Glu and $GABA_A$ receptor for GABA. There have been previous reports of Cr effects on neurons, including Cr as a partial agonist for $GABA_A$ receptors [238-241]. These effects require very high concentrations of Cr (in the ten millimolar range). There was also a report of the opposite effect: that Cr (at a concentration above 500 μM) increased neuronal excitability through NMDA receptors after incubation for 60 mins, with a time course significantly slower than those of classic neurotransmitters [242].

With much longer history of research, ACh and 5-HT now have more evidence in other aspects than Cr as a central transmitter, especially because there are many agonists and antagonists for ACh and 5-HT to prove an additional criterion that is required in some [222,223], but not the majority of, textbooks for a neurotransmitter. The pharmacology criterion will take some time and efforts, because, so far, no efforts have ever been made to find agonists or antagonists for Cr.

Implications of SLC6A8 and Cr

It is notable that SLC6A8 belongs to the neurotransmitter transporter family, with multiple members already shown to transport neurotransmitters [65,66,90-99].

The uptake experiments by others and us indicate that SLC6A8 transports Cr into neurons within the brain. AGAT is also expressed in the brain, but in cells not expressing SLC6A8 [243,244]. Cr and its precursor were thought to be transported between different cells in the nervous system. When SLC6A8 was completely missing, such as in homozygous SLC6A8 deficient patients, Cr treatment was not effective. But, if SLC6A8 was partially active, Cr was effective [245]. Intractable epilepsy in a female with heterozygous SLC6A8 mutation was completely treated by Cr [246]. Our data of inhibitory effect of creatine on cortical neurons might provide a new mechanism to its anti-epileptic activity [247].

The absence of SLC6A8 expression in astrocytes whose endfeet lining microcapillary endothelial cells (MCEC) form the blood-brain barrier (BBB) indicates that Cr in the brain does not rely on import from the periphery and is instead mainly

synthesized in the brain [80,82,248]. SLC6A8 functions within the brain to transport Cr and its precursors, not as a major contributor of Cr transport across the BBB. It is thought to mediate Cr uptake into the presynaptic terminal, based on studies of synaptosomes (Fig. 8) [221].

Cr is known to have effects other than an energy source, and Cr supplement has been thought to be beneficial for children, pregnant and lactating women, and old people [79,249]. Cr has been reported to improve human mental performance [250-255]. Cr has been used as potential treatment in animal models of neurodegenerative diseases [256,257].

Our work will stimulate further research to distinguish which of the previously suspected effects of Cr is not attributed to its role as an energy storage, but can be attributed to its role as a neurotransmitter.

Search for new neurotransmitters

Our work may stimulate the search for more neurotransmitters. Our discovery indicates that the hunt for neurotransmitters stopped decades ago because of technical difficulties, not due to absence of more neurotransmitters. The fact that most of the known small molecule neurotransmitters have been found because of their peripheral effects also argues that what is missing is the concerted efforts to uncover central neurotransmitters with no peripheral effects. New neurotransmitters may be discovered from candidates which have been long suspected, and from previously unsuspected molecules or even previously unknown molecules.

Innovative approaches should be taken to uncover molecules with no previous suspicions or hints. Highly purified SVs, SVs from different regions of the brain, SVs with specific SLCs offer some of the starting points for future research.

Acknowledgements

We are grateful to Drs. Xiaohui Zhang, Xinxiang Zhang, Minmin Luo, Qingchun Guo, Wuping Ge for discussion, suggestions and technical support, to Jiang Chen, Jing Cai, Yulin Jiang, Jinhuan Ou and Xiaomeng Deng for technical assistance, to CIBR, Peking-Tsinghua Center for Life Sciences, Changping Laboratory, Chinese Academy of Medical Sciences (2019RU003) for support.

Author contributions

YR conceived the idea of searching for new neurotransmitters and supervised the project. JZ and XJ tried different approaches to find new neurotransmitters. XB improved the methods, carried out experiments and supervised technicians to carry out the experiments for this paper. XB, JZ, XJ and SY reproducibly found Cr in SVs in independent experiments. WL carried out the uptake experiments. ZL carried out experiments. YR, XB, XJ and JZ wrote the manuscript.

Figure legends

Fig. 1| Presence of Cr in SVs from the mouse brain. (**a**) Representative raw traces from CE-MS of indicated molecules from samples immunoisolated by the control IgG (blue) at 0-2 ºC, the monoclonal anti-Syp antibody at 0-2 ºC (red) and the anti-Syp antibody at room temperature (RT, green). Q1/Q3 for identifying targets were indicated. (**b**-**g**) Quantification of the amounts of indicated molecules. The amount of a molecule was divided by the amount of the anti-Syp antibody bound to magnetic beads. Note Glu (**b**), GABA(**c**), ACh (**d**), 5-HT (**e**), Cr (**f**), but not alanine (**g**) was higher in SVs pulled down by the anti-Syp antibody at 0-2 ^{o}C than those pulled down by the IgG control or those pulled down at the RT. n=14 per group, ***, p<0.001, ns, not significant. one-way ANOVA with Tukey's correction.

Fig. 2| SLC6A8 and Cr in SVs. (**a**) A schematic illustration of the strategy for generating SLC6A8 knockouts using CRISPR/Cas9. An iCreERT2-WPRE-pA cassette (~3.5 kb) was inserted immediately downstream of ATG in the SLC6A8 gene, substituting bp 4 to bp 51 in exon 1 (E1). (**b**) Representative raw traces of Creatine immunoisolated by control IgG from WT mice (blue), the anti-Syp antibody from WT mice (red), IgG from SLC6A8 KO mice (blue) and the anti-Syp antibody from SLC6A8 KO mice (red). (**c**-**h**) Quantification of indicated molecules. Note the selective reduction of Cr in SVs from SLC6A8 KO mice. n=10 per group. ***, p<0.001, ns, not significant. one-way ANOVA with Tukey's correction.

Fig. 3| Reduction of SV Cr in AGAT knockout mice. (**a**) Representative raw traces of Creatine, pulled down by IgG or anti-Syp from $AGAT^{+/+}$, $AGAT^{+/-}$ and $AGAT^{-/-}$ mice. (**b-g**) Quantification of indicated molecules. Cr was significantly decreased in $AGAT^{-/-}$ mice as compared to Cr in $AGAT^{+/+}$ or $AGAT^{+/-}$ mice (**b**). GABA was significantly decreased in SVs from $AGAT^{-/-}$ mice as compared to $AGAT^{+/+}$ mice (**d**) but the difference was smaller than that of Cr. Glu (**c**), ACh (**e**), 5-HT (**f**) and alanine was not different among $AGAT^{+/+}$, $AGAT^{+/-}$ and $AGAT^{-/-}$ mice. n=10 per group. ***, $p<0.001$, ns, not significant. one-way ANOVA with Tukey's correction.

Fig. 4| Expression pattern of SLC6a8. (**a**) A diagram illustrating the generation of SLC6A8-HA KI mice. 3*HA, T2A and CreERT2 were inserted in-frame, before the stop codon, to the C terminus of SLC6A8 protein. (**b-k**) Low magnification photomicrographs of coronal sections immunohistochemically labelled with the anti-HA antibody in SLC6A8-HA mice. (**l** and **m**) immunostaining with the anti-HA antibody in control WT mice. Abbreviations: Pir, piriform cortex; M, motor cortex; LS: lateral septum; Hp: hippocampus; Hb, habenular nucleus; Vp: ventral posterior nucleus of thalamus; Au auditory cortex; Amyg: amygdala; Ip, interpeduncular nucleus; Pn; pontine nucleus; Cb, cerebellum; Pr, prepositus; SC, Superior colliculus; MVe, medial vestibular nucleus. Scale bar: 500 μm.

Fig. 5| Cr release in brain slices from WT and SLC6a8 knockout mice. (**a**) Neuronal depolarization induced by 70 mM K^+ and time points for collecting the

release sample. “Control” samples were collected 1.5 min to 0.5 min before K^+ stimulation, “70 mM K^+” ACSF samples were collected during 70 mM K^+ stimulation, and “wash” samples were collected 10 mins after washout with ACSF. Efflux of Glu (**b**), GABA (**c**) or Cr (**d**) from WT or SLC6A8 KO male mice. Note that a small amount of Cr released in SLC6A8 KO mice did not return to the baseline after 10 mins of washing. (**e-g**) Ca^{2+} dependent release of Glu, GABA and Cr in WT and SLC6A8 KO mice. ***, $p<0.001$, ns, not significant. one-way ANOVA with Tukey’s correction. #, $p<0.05$, ##, $p<0.01$, paired t test.

Fig. 6| Cr release in WT and AGAT knockout mice. (**a**) A schematic diagram illustrating the strategy of AGAT knockout first. With the AGAT gene (also known as GATM) shown in the upper part, and the gene targeting strategy in the lower part. The homologous arm is approximately 10 kb. A targeting cassette, containing Frt-flanked lacZ and neomycin, was inserted downstream of exon 2. At the same time, exon 3 of AGAT was flanked by two loxP sites. K^+ induced release of Glu (**c**) and GABA (**d**) were not significantly different among $AGAT^{+/+}$, $AGAT^{+/-}$ and $AGAT^{-/-}$ mice, whereas that of Cr (**b**) was significantly lower in $AGAT^{-/-}$ mice than those in $AGAT^{+/+}$ and $AGAT^{+/-}$ mice.

Fig. 7| Inhibitory effects of Cr on cortical neurons. (**a**) A photograph showing recording at layer 4 in the somatosensory cortex. Scale bar: 10 μm. (**b**) Patch-clamp recording of a pyramidal neuron. Scale bar: 10 μm. (**c**) Ratios of Cr -responsive and

-unresponsive neurons in the region. (**d**) Representative raw electrophysiological traces showing inhibition of evoked firing by Cr, with the lower panel showing the stimulus protocol. (**e**) Evoked spike numbers in response to different current injections from (**d**). (**f**) Relationship between evoked spike numbers and different current injections to neurons that were inhibited by Cr (n=16). (**g**) The same for Cr-unresponsive neurons (n=35). (**h**) Rheobase for Cr responsive neurons. (**i**) Evoked spike number when these neurons were injected with current of rheobase + 50 pA. (**j**) input resistance. *, $p<0.05$; **, $p<0.01$; ***, $p<0.001$, paired t test.

Fig. 8| Cr uptake into synaptosomes and SVs. (**a**) Markers for subcellular organelles detected in synaptosomes prepared from WT mice or mice with Slc6a8 gene fused in frame to the HA epitope. SLC6A8-HA was enriched in synaptosomes (Sy or 4-Sy) or crude synaptosomes (P2) (see methods), as were other markers for the subcellular organelles in synaptosomes but not the marker for myelin (MBP). (**b**) Representative electron micrographs and histograms of size distribution in synaptosomes isolated from WT ($Slc6a8^{+}/Y$) and *Slc6a8* KO ($Slc6a8^{-}/Y$) mice by Ficoll density-gradient centrifugation. Sy, synaptosome; SV, synaptic vesicles; Mt, mitochondria; PSD, post-synaptic density. Bar, 20 nm. (**c**) Cr uptake into synaptosomes (n=5 per group). The two left columns were results from WT mice and the two right columns from Slc6a8 knockout mice. The control baseline was [^{14}C]-Cr uptake at 0 ºC at 10 mins (*205*). Cr uptake into synaptosomes at 37 ºC measured at 10 mins was observed in WT synaptosomes. Uptake into *Slc6a8* knockout synaptosomes was significantly reduced

when compared to the WT synaptosomes. ***, $p<0.001$, one-way ANOVA with Tukey's correction. (**d**) uptake of [^{13}C]-Cr into immunoisolated SVs in the presence or absence of ATP. ***, $p<0.001$, t test.

Supplementary materials.

Extended Data Figures 1-12.

Materials and methods.

Extended Data Fig. 1| Validation of SV purification from the mouse brain. (**a**) A diagram for SV purification and SV content analysis. Brain homogenates were centrifugated at 35000 g for 25 mins and supernatants containing SVs were collected as the starting material. Following immunopurification by the anti-Syn antibody, SVs were broken by water to release their contents. Metabolites were analyzed by CE-MS. (**b**) EM of SVs captured by the anti-Syn antibody. Arrows pointing to SVs, the size each being 40.4± 0.26 nm, with size distribution shown on the right. (**c**) Analysis of SV purity by immunoblotting. Markers for SVs (Syp, syt, H^+-ATPase, syb2, SV2A, VGLU1, VGLU2 and VGAT) were effectively pulled down by beads coated with the anti-Syn antibody but not by those coated with IgG. Non-SV markers present in supernatants, including those for the lysosome (LAMP1, cathepasinB, LC3B), the Golgi apparatus (GM130, Golgi 97), the early endosome (EEA1), the cytoplasma (GAPDH), synaptic membrane (SNAP23) and postsynaptic components (PSD95, GluN1), the mitochondria (VDAC), the cytoplasmic membrane (CACNA1A), axonal

membrane (GluT4), and glia membrane (MBP), could not be pulled down by either the anti-Syp antibody or IgG.

Extended Data Fig. 2| **Effects of pharmacological inhibitors on SV contents.** (**a**) Cr (**b**) Glu (**c**) GABA (**d**) ACh (**e**) 5-HT (**f**) Alanine*, p<0.5, **p<0.05, ***, p<0.01, one-way ANOVA with Tukey's correction (n=4 per group). Data were normalized to average amount of molecules pulled down by the anti-Syp antibody. NIG, nigrecin.

Extended Data Figure 3| Validation of SLC6A8 knockout mice. (**a**) RT-PCR analysis of full-length coding sequences showing absence of SLC6A8 mRNA expression in brains from hemizygous ($SLC6A8^{-/Y}$) male knockout mice. GAPDH serves as the control. (**b**) Detection of SLC6A8 mRNA expression in female mice, showing reduced expression in heterozygous ($SLC6A8^{+/-}$) and loss of SLC6A8 expression in homozygous ($SLC6A8^{-/-}$) knockout mice. (**c** and **d**) Quantitative RT-PCR analysis. The average values of SLC6A8 mRNA/GAPDH in WT mice ($SLC6a8^{+/Y}$ males in **d** and $SLC6A8^{+/+}$ females in **e**) were set to 1. **, p<0.01 in (**d**), student t test. *** in (**e**), p<0.001, one-way ANOVA with Tukey's correction (n=4 mice per group).

Extended Data Fig. 4| Brain and body weights of SLC6a8 knockout mice. (**a**) Brain weights of male mice. (**b**) Body weights of male mice. (**c**) Brain weight of female mice. (**d**) Body weights of female mice. **, p<0.01 in (B), student t test. *, p<0.05, **,

p<0.01,*** in (**e**), p<0.001, one-way ANOVA with Tukey's correction (n=5 mice per group, 7 weeks old).

Extended Data Fig. 5| Representative CE-MS data of molecules. (**a**-**e**) Molecules pull-down from WT mice by IgG (WT-IgG), anti-Syp antibody (WT-Syp), and those from knockout mice (SLC6A8KO-IgG, SLC6A8 KO-Syp). (**A**) Glu. (**b**) GABA. (**c**) ACh. (**d**) 5-HT. (**e**) Alanine. Vertical: signal amplitude; abscissa: retention time.

Extended Data Fig. 6| Proteins and small molecules detected in SVs from WT and SLC6a8 KO mice. (**a**) Immunoblotting analysis of SV markers Syp, syt, H-ATPase and postsynaptic components (PSD95). (**b**-**d**) Peak areas of CE-MS signals for neurotransmitters: Glu, GABA, and ACh. These neurotransmitters are enriched in SVs and not affected by SLC6A8 genotypes. (**e**) Alanine was not enriched in SVs of either WT or SLC6A8 KO mice. (**f**) Representative raw example traces of Cr. (**g**) Cr in SVs was lower in SLC6A8 KO mice than that in WT mice. **, p<0.01, ***, p<0.001, one-way ANOVA with Tukey's correction (n=14 samples per group).

Extended Data Fig. 7| Validation AGAT-KO first mice. (**a**) RT-PCR analysis of the entire coding region showing the absence of AGAT mRNA in $AGAT^{-/-}$ mice and decreased expression in $AGAT^{+/-}$ mice. (**b**) Quantitative RT-PCR analysis. ***, p<0.001, one-way ANOVA with Tukey's correction (n=4 mice per group).

Extended Data Fig. 8| Brain and body weights of *Agat* $^{+/+}$, *Agat* $^{+/-}$ and *Agat* $^{-/-}$ mice. (**a**) Brain weights of male mice. (**b**) Body weights of male mice. *, $p<0.05$, **, $p<0.01$, * in (**e**), $p<0.001$, one-way ANOVA with Tukey's correction, ns, not significant. (n=5 mice per group,7- weeks).

Extended Data Fig. 9| Similar amounts of SVs pulled down from *Agat* $^{+/+}$, *Agat* $^{+/-}$ and *Agat* $^{-/-}$ mice. (**a**) Representative Western analysis of SV markers H^+-ATPase, Syt and Syp from input, samples pulled down by IgG (IgG-P) and anti-Syp antibody (Syp-P). (**b**-**e**) Quantification of protein band densities for Syp (**b**), Syt (**c**) and H^+-ATPase (**d**) (n=20 per group).

Extended Data Fig. 10| Layer distribution of recording sites in the somatosensory cortex. (**a**) High levels of SLC6A-HA signal observed in the somatosensory cortex, especially in layer 4. (**b**) Recording sites. Red denotes the responsive neurons and blue the unresponsive neurons.

Extended Data Fig. 11| Electrophysiological parameters of Cr-responsive (blue) and Cr-nonresponsive neurons (red). There was no significant difference between the two groups of neurons in membrane capacitance (Cm) (**a**) and membrane resistance (Rm) (**b**), resting membrane potential (RMP) (**c**), spike threshold (**d**), spike amplitude (**e**), half width of spike (**f**) and amplitude of after hyperpolarization (AHP) (**g**). While no electrical parameters detected were changed by Cr in non-responsive neurons

(n=35), resting membrane potential was slightly inhibited by Cr and AHP was slightly elevated (n= 16) (*, $p<0.05$, paired t test).

Extended Data Fig. 12| Electrophysiological daata of Cr-unresponsive neurons. (**a**) Representative raw traces. (**b**) I-V curve of this same neuron. No effect of 100 μM Cr on rheobase current and evoked spike number at a current of 50 pA above rheobase current was observed.

Materials and methods

Generation of knockout and knockin mice.

SLC6A8 knockout and knockin mice were generated using CRISPR-Cas9-mediated genome engineering techniques by Beijing Biocytogen (Beijing, China). AGAT 'knockout-first' [185] mice were purchased from CAM-SU GRC (Suzhou, China). All mutations were validated by southern blot analysis, tail junction PCR and DNA sequencing.

Reverse-transcription polymerase chain reaction (RT-PCR) and quantitative real-time PCR (qPCR).

Total RNA of whole brains from mice of different genotypes was extracted using the Buffer RZ (Tiangen, no. RK14, Beijing, China) and reverse transcribed into complementary DNA (cDNA) using the RevertAid First-Strand cDNA synthesis kit (Thermo Scientific, K1622, USA). qPCR was performed using the Taq Pro Universal SYBR qPCR Master Mix (Vazyme, Q712-02) on Bio-Rad CFX-96 Touch Real-time

PCR System (Bio-Rad, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. ΔCt (difference in cycle threshold) was calculated for each sample ($\Delta Ct = Ct_{Target\ gene} - Ct_{GAPDH}$) for further evaluation of relative mRNA expression levels in different genotypes. The sequence specificities of the primers were examined. Three pairs of primers targeting different genes were used: SLC6a8 forward, 5'-GTCTGGTGACGAGAAGAAGGG-3', Slc6a8 reverse, 5'-CCACGCACGACATGATGAAGT -3'; AGAT forward, 5'-CACAGTGGAGGTGAAGGCCAATACATAT-3', AGAT reverse, 5'-CCGCCTCACGGTCACTCCT-3'; GAPDH forward, 5'-AGGTCGGTGTGAACGGATTTG -3', GAPDH reverse, 5'-TGTAGACCATGTAGTTGAGGTCA-3'.

Primers for reverse PCR were designed to obtain complete coding sequences based on information obtained from National Center for Biotechnology Information (NCBI): SLC6A8 forward, 5'-ATGGCGAAAAAGAGCGCTGAAAACG-3'; Slc6a8 reverse, 5'-TTACATGACACTCTCCACCACGACGACC-3'; AGAT forward, 5'-ATGCTACGGGTGCGGTGTCT-3'; AGAT reverse, 5'-TCAGTCAAAGTAGGACTGAAGGGTGCCT-3'. PCR products were electrophoresed on 1% agarose gels, stained with GelRed, visualized under UV illumination and photographed.

Immunoblot analysis.

Samples were loaded onto 10% polyacrylamide gels with the PAGE system (#1610183, Bio-Rad Laboratories, USA) and run in the SDS running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.8) for 25 min at 80 V followed by 25 - 45 min at 200 V. Afterward, proteins were transferred to immobilon NC transfer membranes (HATF00010, Millipore) at 400 mA for 2 h in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol). Membranes were blocked in 5% fat-free milk powder in TBST (25 mM Tris, 150 mM NaCl, 0.2%Tween-20 (P1397, Sigma), pH 7.4 adjusted with HCl) and incubated overnight with the indicated primary antibodies dissolved in TBST containing 2% BSA.

Primary antibodies are listed below: rabbit anti-Synaptophysin (dilution 1:5000, cat no. 101002, SySy, Germany), rabbit anti-Synaptotagmin1/2 (dilution 1:2000, cat no.105002, SySy, Germany), rabbit anti-proton ATPase (dilution 1:1000, cat no.109002, SySy, Germany), rabbit anti-Synaptobrevin 2 (dilution 1:5000, cat no.104202, SySy, Germany), rabbit anti-SV2A (dilution 1:2000, cat no.109003, SySy, Germany), rabbit anti-VGlut1(dilution 1:4000, 135302, SySy, Germany), rabbit anti-VGlut2 (dilution 1:2000, 135402, SySy, Germany), rabbit anti-VGAT(dilution 1:4000, 131002, SySy, Germany), rabbit anti-SNAP23 (dilution 1:2000, cat no. 111202, SySy, Germany), mouse anti-PSD95 (dilution 1:5000, cat no 75028,NeuroMab), mouse anti-GluN1(dilution 1:5000, cat no 114011, SySy, Germany), rabbit anti-GM130 (dilution 1:1000, cat no ab52649, Abcam), rabbit anti-Golgin-97 (dilution 1:2000, cat no13192, Cell Signaling Technology, USA), rabbit anti-EEA1 (dilution 1:2000, cat no 3288, Cell Signaling Technology, USA), rabbit anti-LC3B (dilution

1:1000, cat no 2775S , Cell Signaling Technology, USA), goat anti-CathepsinB (dilution 1:2000, AF965, R&D Systems), rabbit anti-GAPDH (dilution 1:1000, cat no 2118S, Cell Signaling Technology, USA), rabbit anti-GluT4 (dilution 1:1000, ab33780, Abcam), rabbit anti-CACNA1A (dilution 1:300, 152103, SySy, Germany), rabbit anti-VDAC (dilution 1:1000, cat no 4661S , Cell Signaling Technology, USA), rabbit anti-MBP (1:1000 , cat no. 295003, SySy, Germany), mouse anti Creatine Kinase B (dilution 1:5000, cat no MAB9076, R&D Systems), rabbit anti HA (dilution 1:2000, CST3724; Cell Signaling Technology, USA) and rabbit anti SNAP25 (dilution 1:2000, ab109105, Abcam) antibodies.

Membranes were washed in three washing steps in TBST (each for 5 mins) and incubated with peroxidase-conjugated secondary antibodies for 2-3 h at 4 ºC. The second antibody used were anti-rabbit (dilution 1:5000, A6154, Sigma), anti-mouse (dilution 1:5000, 715-035-150, Jackson Immuno Research) or rabbit anti-goat IgG secondary antibodies (dilution 1:1000, cat no ab6741, Abcam). After repeated washing, signals were visualized using a ChemiDoc XRS$^+$ System (Bio-RAD Laboratories, USA).

Isolation of synaptic vesicles.

Our purification procedures for synaptic vesicles were based on previously established immunoisolation methods [143,151]. Protein G magnetic beads (cat no.88848, Thermofisher Scienctific) were washed three times with IP buffer (100 mM potassium tartrate, 4 mM HEPES-KOH, 2 mM $MgCl_2$, pH 7.4) supplemented with a

complete protease inhibitor cocktail (Roche). 5 μg monoclonal anti-Syp antibody directed against a cytoplasmic epitope (cat no 101011, synaptic systems, Germany) or control mouse IgG (10400C, Thermofisher Scientific) was used to incubate with 20-30 μl beads for 30 mins at RT in 2% BSA dissolved in IP buffer. Under this condition, 4-4.5 μg of antibody was coupled, as determined by Western blot and Commassie Blue staining. Immunoisolation of SVs were carried out at 0 °C-2 °C to prevent vesicular content leakage (with RT as a control). Briefly, the whole mouse brain was homogenized in 3 ml of IP buffer with a glass/Teflon homogenizer (20 strokes at 2000 rpm, WHEATON, USA and WIGGENS WB2000-M, Germany) immediately after decapitation. Homogenates were centrifuged for 25 mins at 35,000 x g and the supernatant was adjusted to approximately 3 mg/ml protein (Nanodrop 2000 C, Thermofisher Scientific). To capture the SVs for content detection, about 200 μl of supernatants (per 5 μg anti-Syp/IgG) were incubated with pre-coupled beads for 2.25 h under slow rotation at 2 °C. Beads were washed 6 times for further Western blot analysis and vesicular content detection. For pharmacological blockade of H^+-gradient across SV membrane, the mix of supernatants and pre-coupled beads was diluted into 1.2 ml before the addition of inhibitors.

Determination of vesicular contents

To extract SV contents, immunoisolates were treated with 50 μl ultra-pure water. 100 μl methanol together with 100 μl acetonitrile were added to precipitate proteins in samples. After centrifugation for 20 mins at 168000 × g, supernatants were collected

and centrifuged for 20 mins at 2000 × g to remove beads and proteins. Samples were pre-frozen with liquid nitrogen and vacuum dried at -45 °C overnight. Dried samples were kept frozen and re-suspended with 50 μl of 0.2 μM ^{13}C-creatine (internal control) immediately before detection.

Capillary electrophoresis-mass spectrometry (CE-MS) was used to verify and quantify small molecules. CE/MS detection was applied with the coupling of PA800 plus CE system (Beckman Coulter, Brea, CA, USA) and mass spectrometry (TRIPLE QUAD 5500, AB SCIEX or Q Exactive HF-X, Thermo Scientific). Before SV content detection, we optimized MS detection of classical neuro transmitters, Cr and amino acids in positive ion mode. Firstly, the fragment ions (Q3) for a given molecule (precursor ions, Q1) were determined by either systematic scanning of standard sample solution (0.1 μM in 10% acetate acid) or referring to database (www.mzcloud.org). Secondly, optimal values of collision energy (CE), collision cell exit potential (CXP) and declustering potentials (DP) were determined for each pair of Q1/Q3. Thirdly, optimal combination of parameters (Q1/Q3, CE, CXP, DP) was chosen for each molecule. In addition, parameters were adjusted every 2 to 3 months for best signal to noise ratios.

CE/MS separations were carried out by capillaries (OptiMS silica surface cartridge, BECKMAN COULTER). The CE background electrolyte was 10 % acetate acid. Each new separation capillary was activated with rinsing under100 psi sequentially with methanol for 10 mins (forward), methanol for 3 mins (reverse), H_2O for 10 mins (forward), H_2O for 3 mins (reverse), 0.1 M NaOH for 10 mins (forward), water for 5

mins (reverse), 0.1 M HCl for 10 mins (forward), followed by water for 10 mins and then 10 % acetate acid for 10 mins (forward) and 3 mins (reverse), prior to the first use. Between analyses, the capillary was rinsed with 10% acetate acid under a 100 psi pressure for 5 min (forward) flowed by 75 psi for 4 min. The sample (50 μl) was injected with 2.5-4 psi for 30 s. Separation voltage of 25 kV was applied for 25 mins. To maintain stably spray during CE separation, ion spray voltage was applied at 1.7-1.9 kV. MS data were collected 5 mins after CE separation. Finally, the capillary was washed with 10% acetate acid for 10 mins, followed by methanol for 20 min and then10% acetate acid for 20 mins.

Standard solutions of 0.2 μM ^{13}C-Cr (internal control) and analytes were used to plot standard curves. Linear standard curves (R^2>0.98, for most cases, R^2>0.99), calculated from peak area ratios corresponding to analytes and internal standards, were obtained for all molecules tested. The concentration ranges used for standards of Glu, GABA, ACh, 5-HT, Cr and alanine were 0.03-10 μM, 0.003-1 μM, 0.0003-0.1 μM, 0.003-1 μM, 0.03-1 μM and 0.03-1 μM, respectively. Standard curves were made at least twice for a given capillary. Analytes of SV contents were calculated using the standard curves and normalized to the amount of anti-Syp antibody conjugated to the beads.

Electron microscopy.

All EM grids were glow discharged for 30 s using a plasma cleaner (Harrick PDC-32G-2). To free SVs from beads, 25 μl 0.1 M glycine-HCl (PH=2) was incubated

for 1 min and quickly neutralized with 25 μl 0.1 M Tris (pH=10). Beads were quickly removed and 2-4 μL aliquots of SVs were applied to the carbon coated copper grids (Zhong Jing Ke Yi, Beijing). After 1 min, the grid was dried with a filter paper (Whatman No.1), and placed in the water, and then immediately stained using 2 % uranyl acetate for 30 s. At last uranyl acetate was removed and the grid was air dried. The grids were examined on a JEM-F200 electron microscope (JEOL, Japan) operated at 200 kV. Images were recorded using a 4k × 4k COMS One view camera (Gatan). Fixation of synaptosomal pellets was performed by immersion with pre-warmed 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) at RT for 2 h. After washing 4 times with 0.1 M phosphate buffer (pH 7.4) every 15 mins, samples were post-fixed with 1% osmium tetroxide (w/v) at 4°C for 1 h and then washed 3 times. Following en bloc staining with 2% uranyl acetate (w/v) at 4°C overnight, samples were dehydrated and embedded in fresh resin, polymerized at 65°C for 24 h. Ultrathin (70 nm) sections were obtained by Leica UC7 ultramicrotome (Leica Microsystems, German) and recorded on 80 kV in a JEOL Jem-1400 transmission electron-microscope (JEOL, Japan) using a CMOS camera (XAROSA, EMSIS)

Immunohistochemistry.

Adult mice were anesthetized by *i.p.* injection with 2 % 2,2,2-tribromoethanol (T48402, Sigma Aldrich) in saline at a dose of 400 mg/kg, and perfused trancardially with 0.9 % saline followed by 4 % PFA in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na_2HPO_4, 1.8 mM KH_2PO_4, pH=7.4).

Brains were cryoprotected with 30 % sucrose in 30 % sucrose 0.1 M PB (81 mM Na_2HPO_4, 19 mM NaH_2PO_4) and sectioned in the coronal plane (40 μm thick) using a Cryostat (Leica 3050S). For anti-HA immunostaining, we used a rabbit monoclonal anti-HA antibody (1:500 in 0.3 % Triton in PBS; 48 h incubation at 4 °C; #3724, Cell Signaling Technology), followed by a goat anti-rabbit Alexa Fluor 546 secondary antibody (1:1000; overnight at 4 °C; # A-11035, Invitrogen). Sections were mounted in a medium containing 50 % glycerol, cover-slipped, and sealed with nail polish. Images were acquired using virtual slide microscope (Olympus VS120-S6-W) and a laser-scanning confocal microscope (Zesis 710) and brain structures inferred with an established mouse brain atlas [258].

Preparations of brain slices.

Male C57 mice (of 30-38 days-old) were anesthetized with pentobarbital (250 mg/kg) and decapitated. Brains were quickly removed and placed into ice-cold, low calcium, high magnesium artificial cerebrospinal fluid (ACSF) with sodium replaced by choline. The medium consisted of 120 mM choline chloride, 2.5 mM KCl, 7 mM $MgSO_4$, 0.5 mM $CaCl_2$, 1.25 mM NaH_2PO_4, 5 mM sodium ascorbate, 3 mM sodium pyruvate, 26 mM $NaHCO_3$, and 25 mM D-(+)-glucose, and was pre-equilibrated with 95% O_2-5% CO_2. Coronal brain slices (300 μm thick) were cut with a vibratome (Leica VT1200S). Slices were incubated for 1 h at 34°C with oxygenated ACSF containing: 124 mM NaCl, 2.5 mM KCl, 2 mM $MgSO_4$, 2.5 mM $CaCl_2$, 1.25 mM NaH_2PO_4, 26 mM $NaHCO_3$, and 10 mM D- (+)-glucose.

Evoked release from brain slices.

Coronal brain slices (each 300 μm thick, typically with a wet weight of 17-20 mg) were transferred into a specially designed superfusion chamber with a volume of approximately 200 μl, containing freshly 95% O_2/5% CO_2 oxygenated ACSF. Slices were equilibrated for 10 min in ACSF at a superfusion rate of 0.9-1.25 ml/min. The "control" sample was collected for 1 min just before high K^+ stimulation (K-ACSF, 70 mM KCl replacing equal amount of NaCl). We waited for 30 seconds to allow K^+ stimulus to immerse the slices (dead volume for solution transition of 200 μl and chamber volume of 200 μl), then the sample "70 mM K" in response to K-ACSF was collected for another 1 min. Following 10 min of washout period, we collected the third sample of "wash" for 1 min.

To detect Ca^{2+} dependent release, slices were pre-incubated for 10 mins with normal ACSF and equilibrated with Ca^{2+} free ACSF (containing 1 mM EGTA to chelate extracellular Ca^{2+}) for 10 mins. The baseline sample "0 Ca^{2+} ACSF" was collected for 1 min. Superfusion solution was changed to Ca^{2+} free K-ACSF for 2 mins and sample "0 Ca^{2+} 70 mM K" was collected (dead volume for solution transition of 400 μl and chamber volume of 200 μl). After that, the solution was changed back to normal ACSF for 10 mins and K-ACSF for 2 mins. The sample "2.5 mM Ca 70 mM K" for the last min was collected.

Samples were subjected to CE-MS in a method similar to SV content detection, except for the following: 1) standards were dissolved in ACSF or other buffers used in

release experiment; 2) concentration ranges used for standards of Glu was from 0.003-1 μM. 3) To protect the MS from salt pollution, data were collected from 10 mins - 20 mins during CE separation.

Patch-Clamp recordings.

Slices were transferred to a recording chamber on an upright fluorescent microscope equipped with differential interference contrast optics (DIC; Olympus BX51WI). Slices were submerged and superfused with ACSF at about 2.8 ml/min at 24-26 °C. Whole cell patch recordings were routinely achieved from layer 4/5 medium sized pyramidal neurons from the somatosensory cortex. Patch pipettes (3-5 MΩ) contained: 140 mM K-gluconate, 10 mM HEPES, 0.5 mM EGTA, 5 mM KCl, 3 mM Na_2-ATP, 0.5 mM Na_3GTP, and 4 mM $MgCl_2$ (with pH adjusted to 7.3 and osmolarity of 290 mOsm/kg). Current-clamp recordings were carried out with a computer-controlled amplifier (Multiclamp 700B, Molecular Devices) and traces were digitized at 10 kHz (DigiData 1550B, Molecular Devices). Data were collected and analyzed using Clampfitor Clampex 10 software (Molecular Devices).

Cells were characterized by their membrane responses and firing patterns during hyperpolarizing and depolarizing current steps (-100 to +500 pA, increment: 50 pA or 25 pA, 500 ms). Regular spiking pyramidal neurons were identified by moderate maximal spiking frequencies (20-60 Hz, that is, 10-30 spikes per 500 ms, Figs. 7 **e**-**g**), increasing of inter-spike intervals during depolarizing step (Fig. 7**b** and Extended Data Fig. 11**a**), high action amplitude (Extended Data Fig. 12**e**) and large half width

(Extended Data Fig. 12**f**) [201,202]. After the mean firing frequency evoked by current injections reached the steady state for at least 5 mins (typically 20-30 mins following the formation of whole-cell configuration), 100 μM Cr was bath-applied for 6 mins. Typically, Cr was applied for a 2nd time following washout to re-confirm the effects.

Synaptosome preparation.

Synaptosomes were isolated by Ficoll/sucrose density-gradient centrifugation [203,209,221,259]. Whole brains from adult male mice were homogenized with 15 strokes at 900 rpm in buffer A (320 mM sucrose, 1 mM EDTA, 1mM EGTA, 10 mM Tris–HCl, pH 7.4, with a complete protease inhibitor cocktail (Roche)). The homogenate (H fraction) was centrifuged at 1000 g for 10 min to precipitate the membrane fragments and nuclei (P1 fraction). Supernatant was centrifuged again at 1000 g for 10 min and the resulting supernatant (S1) was centrifuged at 12,000 g for 20 min. Supernatant was the S2 fraction, and the pellet was re-suspended with buffer A and centrifuged at 12,000 g for 20 min. The resulting pellet was crude synaptosomes (P2 fraction), containing synaptosomes with mitochondria and microsomes.

Crude synaptosomes (P2 fraction) was re-suspended with 150-200 μl buffer B (320 mM sucrose and 10 mM Tris–HCI (pH 7.4)). The sample was carefully overlaid on the top of a gradient of 2 ml of 7.5 % (wt/vol in buffer B) Ficoll and 1.8 ml of 13% (wt/vol in buffer B) Ficoll and centrifuged at 98,000 g for 45 min at 2-4 °C in a swinging-bucket rotor. A myelin band was present near the surface, and th synaptosomes band (fraction Sy) was present at the interface between the 13% and 7.5 %

Ficoll layers, with the mitochondria being pelleted at the bottom. For further western analysis, the supernatant was divided into 6 fractions (600 μl for each fraction) and the mitochondria pellet was discarded. The isolated synaptosomes was included in fraction 4.

For Western analysis, fractions H, S1, P1, S2, P2 and Sy were adjusted to 0.5 mg/ml by bicinchoninic acid assay (BCA) method with reference to NanoDrop™ 2000 Spectrophotometers. 3.35 μg protein was loaded for each lane. Fractions 1- 6 were loaded with the same volume (10 μl composed of 6.7 μl sample and 3.3 μl loading buffer) for each lane.

Creatine uptake into synaptosomes

To remove Ficoll, we diluted the synaptosomal band (480 μl) with 4.3 ml of a pH 7.4 buffer C containing (in mM) 240 mannitol, 10 glucose, 4.8 Kgluconate, 2.2 Cagluconate, 1.2 MgSO4, 1.2 KH_2PO4 and 25 HEPES-Tris. The sample was then centrifuged at 12,000 g and the pellet was re-suspended with buffer C. Uptake experiments were either performed at 37ºC or at 0ºC (control). For each sample, 25-43 μg of synaptosomes (with a volume of 40-50 μl) were added to 360 μl buffer containing (in mmol/L) 100 NaCl, 40 mannitol, 10 glucose, 4.8 Kgluconate, 2.2 Cagluconate, 1.2 $MgSO_4$, 1.2 $KH2PO_4$, 25 HEPES and 25 Tris (pH adjusted to 7.4). A mixture of 18 μM [^{14}C]-creatine (0.4 μCi) and 5 μM creatine was quickly added. After 10 min, uptake was terminated by the addition of 1 ml of NaCl-free ice-cold buffer C. Samples were immediately filtered, under vacuum, through a Whatman GF/C glass filter (1825-025) pre-wetted with buffer C. Filters were further washed with 10 ml of ice-cold buffer C,

dissolved in scintillation fluid and the radioactivity determined by liquid scintillation spectrometry.

Creatine uptake into SVs

The uptake of ^{13}C-creatine was assayed according to a conventional procedure [260] with slight modifications: the immunoisolated synaptic vesicles by 10 μg Syp antibody (101011, Synaptic Systems, Germany) were resuspended with the uptake buffer (150mM meglumine-tartrate, 4 mM KCl, 4 mM $MgSO_4$, 10mM HEPES-KOH pH 7.4, and complete EDTA-free protease inhibitor cocktail) containing 4mM Mg-ATP or additional 4mM MgSO4, followed by preincubation for 5 min at 25□. The uptake reaction was started by addition of 1mM ^{13}C-creatine dissolved in the uptake buffer with a final volume of 125μL. After 10min at 25□, 1mL of ice-cold uptake buffer was added to the incubation to stop the reaction, followed by 5 more times washing. The SV contents were extracted using the protocol described in the determination of vesicular contents part. 100 nM ^{13}C-proline was used as the internal control.

HPLC-MS was used to verify and quantify the creatine contents of samples. An Acquity UPLC H-Class system (Waters, MA, USA) coupled to an API 5500 tandem quadrupole mass spectrometer (AB Sciex, USA) were used for HPLC-MS analysis along with SeQuant ZIC-HILIC column (100 mm×2.1 mm, 3.5 μm, Merck Millipore, 150441) in the positive mode. The mobile phase A was 0.1% formic acid in water, and the mobile phase B was 0.1% formic acid in acetonitrile. The gradient was as below 0 min, 80% B; 4 min, 50% B; 9 min, 50% B; 9.5 min, 20% B; 12.5 min, 20% B; 13 min, 80% B; 20 min, 80% B. The flow rate was 300 μL/min, and the column temperature

was 30 °C. 2 µL were injected for each sample resuspended in 50 µL of 80% acetonitrile. The optimization of MS parameters, as well as the data processing, was also described in the determination of vesicular contents part.

References

1 Du Bois-Reymond, E. H. *Gesammelte Abhandlungen zur Allgemeinen Muskel-und Nervenphysik*. (Veit & Co, 1877).

2 Langley, J. N. On the stimulation and paralysis of nerve-cells and of nerve-endings: Part I. *J Physiol* **27**, 224-236, doi:10.1113/jphysiol.1901.sp000868 (1901).

3 Elliot, T. R. On the action of adrenalin. *J Physiol* **31**, xx-xxi (1904).

4 Elliot, T. R. The action of adrenalin. *J Physiol* **32**, 401-467, doi:10.1113/jphysiol.1905.sp001093 (1905).

5 Dale, H. H. The action of certain esters and ethers of choline, and their relation to muscarine. *Journal of Pharmacology and Experimental Therapeutics* **6**, 147-190 (1914).

6 Loewi, O. Über humorale Übertragbarkeit der Herznervenwirkung. *I. Pflüger Archiv Physiol* **189**, 239-242 (1921).

7 Rao, Y. The First Hormone: Adrenaline. *Trends Endocrinol Metab* **30**, 331-334, doi:10.1016/j.tem.2019.03.005 (2019).

8 C, B. *Leçons sur les effets des substances toxiques et médicamenteuses*. (JB Baillière, 1857).

9 Langley, J. N. & Dickinson, W. L. On the Local Paralysis of Peripheral Ganglia, and on the Connexion of Different Classes of Nerve Fibres with Them. *Proceedings of the Royal Society of London* **46**, 423-431 (1889).

10 Langley, J. N. On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. *Journal of Physiology-London* **33**, 374-413, doi:10.1113/jphysiol.1905.sp001128 (1905).

11 Langley, J. N. On nerve endings and on special excitable substances in cells. *Proceedings of the Royal Society of London Series B-Containing Papers of a Biological Character* **78**, 170-194, doi:DOI 10.1098/rspb.1906.0056 (1906).

12 Strecker, A. Ueber einige neue Bestandtheile der Schweinegalle. *Justus Liebigs Annalen der Chemie* **123**, 964-965 (1862).

13 Liebreich, O. Ueber die chemische Beschaffenheit der Gehirnsubstanz. *Justus Liebigs Annalen der Chemie und Pharmacie* **134**, 29-44 (1865).

14 Baeyer, A. Mittheilungen aus dem organischen Laboratorium de Gewerbeacademie zu Berlin. I. Über das Neurin (Notes from the organic

laboratory of the Gewerbeacademie in Berlin. I on the neurin). . *Justus Liebig's Annalen der Chemie* **142**, 322-326 (1867).

15 Hunt, R. & Taveau, R. D. M. On the physiological action of certain cholin derivatives and new methods for detecting cholin. *British Medical Journal* **1906**, 1788-1789 (1906).

16 Mott, F. W. & Halliburton, W. D. The Physiological Action of Choline and Neurine. *Br Med J* **1**, 1082-1083, doi:10.1136/bmj.1.2001.1082 (1899).

17 Hunt, R. Note on a blood pressure lowering body in the suprarenal gland. . *Am J Physiol* **3**, xviii-xix (1900).

18 Ewins, A. J. Acetylcholine, a New Active Principle of Ergot. *Biochem J* **8**, 44-49, doi:10.1042/bj0080044 (1914).

19 Dale, H. H. & Dudley, H. W. The presence of histamine and acetylcholine in the spleen of the ox and the horse. *J Physiol* **68**, 97-123, doi:10.1113/jphysiol.1929.sp002598 (1929).

20 Feldberg, W. & Gaddum, J. H. The chemical transmitter at synapses in a sympathetic ganglion. *J Physiol* **81**, 305-319, doi:10.1113/jphysiol.1934.sp003137 (1934).

21 Brown, G. L. & Feldberg, W. The acetyloholine metabolism of a sympathetic ganglion. *J Physiol* **88**, 265-283, doi:10.1113/jphysiol.1936.sp003439 (1936).

22 Dale, H. H., Feldberg, W. & Vogt, M. Release of acetylcholine at voluntary motor nerve endings. *J Physiol* **86**, 353-380, doi:10.1113/jphysiol.1936.sp003371 (1936).

23 Addison, T. *On the constitutional and local effects of disease of the supra-renal capsules.* . (Highley, 1855).

24 Schäfer, E. A. ON THE PRESENT CONDITION OF OUR KNOWLEDGE REGARDING THE FUNCTIONS OF THE SUPRARENAL CAPSULES. *Br Med J* **1**, 1277-1281 (1908).

25 Oliver, G. & Schäfer, E. A. The Physiological Effects of Extracts of the Suprarenal Capsules. *J Physiol* **18**, 230-276, doi:10.1113/jphysiol.1895.sp000564 (1895).

26 Abel, J. J. On epinephrin, the active constituent of the suprarenal capsule and its compounds. *Proc Am Physiol Soc* **3**, 4-5 (1898).

27 Abel, J. J. & Crawford, A. C. On the blood pressure raising constituent of the suprarenal capsule. *Johns Hopkins Hosp Bull* **8**, 151-157 (1897).

28 Abel, J. J. Über den blutdruckerregenden Bestandtheil der Nebenniere, das Epinephrin. *Hoppe-Seyler's Zeitschrift für physiolgische Chemie* **28**, 318-362 (1899).

29 Abel, J. J. Further observations on epinephrine. *Johns Hopkins Hosp Bull* **12**, 80-84 (1901).

30 Takamine, J. Adrenalin, the active principle of the suprarenal glands and its mode of preparation. *Am J Pharmacy* **73**, 523-531 (1901).

31 Takamine, J. The isolation of the active principle of the suprarenal gland. *J Physiol* **27**, 29-30 (1902).

32 Aldrich, T. B. A preliminary report on the active principle of the suprarenal gland. *Am J Physiol* **5**, 457-461 (1901).
33 Langley, J. N. Observations on the physiological action of extracts of the supra-renal bodies. *J Physiol* **27**, 237-256, doi:10.1113/jphysiol.1901.sp000869 (1901).
34 Barger, G. & Dale, H. H. Chemical structure and sympathomimetic action of amines. *Journal of Physiology* **41**, 19-59 (1910).
35 Cannon, W. B. & Rosenblueth, A. Sympathin E and Sympathin I. *Am J Physiol* **104**, 557-574 (1933).
36 Euler, U. S. v. A specific sympathomimetic ergone in adrenergic nerve fibers (sympathin) and its relation to adrenaline and noradrenaline. *Acta Physiol Scand* **12**, 73-97 (1946).
37 Euler, U. S. v. Identification of the sympathomimetic ergone in adrenergic nerves of cattle (Sympathin N) with laevo-noradrenaline. *Acta Physiol Scand* **16**, 63-74 (1948).
38 Euler, U. S. v. *Noradrenaline. Chemistry, physiology, pharmacology and clinical aspects.* (Springfield, 1956).
39 Mitchell, J. F. The spontaneous and evoked release of acetylcholine from the cerebral cortex. *J Physiol* **165**, 98-116, doi:10.1113/jphysiol.1963.sp007045 (1963).
40 Collier, B. & Mitchell, J. F. The central release of acetylcholine during stimulation of the visual pathway. *J Physiol* **184**, 239-254, doi:10.1113/jphysiol.1966.sp007913 (1966).
41 Collier, B. & Mitchell, J. F. The central release of acetylcholine during consciousness and after brain lesions. *J Physiol* **188**, 83-98, doi:10.1113/jphysiol.1967.sp008125 (1967).
42 Carlsson, A., Falck, B. & Hillarp, N. A. Cellular localization of brain monoamines. *Acta Physiol Scand* **56(Suppl)**, 1-28 (1962).
43 Björklund, A., Ehinger, B. & Falck, B. A method for differentiating dopamine from noradrenaline in tissue sections by microspectrofluorometry. *J Histochem Cytochem* **16**, 263-270, doi:10.1177/16.4.263 (1968).
44 Robbins, J. The effects of amino acids on the crustacean neuro-muscular system. *Anat Rec* **132**, 492-493 (1958).
45 Curtis, D. R., Phillis, J. W. & Watkins, J. C. Chemical excitation of spinal neurones. *Nature* **183**, 611-612, doi:10.1038/183611a0 (1959).
46 Curtis, D. R. & Watkins, J. C. The excitation and depression of spinal neurones by structurally related amino acids. *J Neurochem* **6**, 117-141, doi:10.1111/j.1471-4159.1960.tb13458.x (1960).
47 Curtis, D. R. & Watkins, J. C. Acidic amino acids with strong excitatory actions on mammalian neurones. *J Physiol* **166**, 1-14, doi:10.1113/jphysiol.1963.sp007087 (1963).
48 Roberts, E. & Frankel, S. γ-Aminobutyric acid in brain: its formation from glutamic acid. *J Biol Chem* **187**, 55-63 (1950).

49 Udenfriend, S. Identification of gamma-aminobutyric acid in brain by the isotope derivative method. *J Biol Chem* **187**, 65-69 (1950).
50 Florey, E. An inhibitory and an excitatory factor of mammalian central nervous system, and their action of a single sensory neuron. *Archieves Internationales de Physiologie* **62**, 33-53, doi:10.3109/13813455409145367 (1954).
51 Florey, E. & McLennan, H. The release of an inhibitory substance from mammalian brain, and its effect on peripheral synaptic transmission. *J Physiol* **129**, 384-392, doi:10.1113/jphysiol.1955.sp005361 (1955).
52 Fatt, P. & Katz, B. Some observations on biological noise. *Nature* **166**, 597-598, doi:10.1038/166597a0 (1950).
53 Fatt, P. & Katz, B. Spontaneous subthreshold activity at motor nerve endings. *J Physiol* **117**, 109-128 (1952).
54 Del Castillo, J. & Katz, B. Quantal components of the end-plate potential. *J Physiol* **124**, 560-573, doi:10.1113/jphysiol.1954.sp005129 (1954).
55 Robertson, J. D. Ultrastructure of two invertebrate synapses. *Proc Soc Exp Biol Med* **82**, 219-223, doi:10.3181/00379727-82-20071 (1953).
56 Palade, G. E. & Palay, S. L. Electron microscope observations of interneuronal and neuromuscular synapses. *Anat Rec* **118**, 335-336 (1954).
57 Palay, S. L. Electron microscope study of the cytoplasm of neurons. *Anat Rec* **118**, 336 (1954).
58 De Robertis, E. D. P. & Bennett, H. S. Sub-microscopic vesicle component in the synapse. *Fed Proc* **13**, 35 (1954).
59 De Robertis, E. D. P. & Bennett, H. S. Some features of the sub-microscopic morphology of the synapses in frog and earthworm. *J Biophys Biochem Cytol* **1**, 47–55 (1955).
60 Del Castillo, J. & Katz, B. Biophysical aspects of neuro-muscular transmission. *Prog Biophys* **6**, 121-170 (1956).
61 Axelrod, J., Weil-Malherbe, H. & Tomchick, R. The physiological disposition of H3-epinephrine and its metabolite metanephrine. *J Pharmacol Exp Ther* **127**, 251-256 (1959).
62 Radian, R. & Kanner, B. I. Reconstitution and purification of the sodium- and chloride-coupled gamma-aminobutyric acid transporter from rat brain. *J Biol Chem* **260**, 11859-11865 (1985).
63 Radian, R., Bendahan, A. & Kanner, B. I. Purification and identification of the functional sodium- and chloride-coupled gamma-aminobutyric acid transport glycoprotein from rat brain. *J Biol Chem* **261**, 15437-15441 (1986).
64 Guastella, J. *et al.* Cloning and expression of a rat brain GABA transporter. *Science* **249**, 1303-1306, doi:10.1126/science.1975955 (1990).
65 Pacholczyk, T., Blakely, R. D. & Amara, S. G. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. *Nature* **350**, 350-354, doi:10.1038/350350a0 (1991).
66 Blakely, R. D. *et al.* Cloning and expression of a functional serotonin transporter from rat brain. *Nature* **354**, 66-70, doi:10.1038/354066a0 (1991).

67 Purves, D., Augustine, G.J., Firzpatrick, D., Katz, L., LaMantia, A.-S., McNamara, J.O.,, and Williamss, S.M. *Neuroscience, 2nd edition*. (Sinauer Associates, 2001).

68 Purves, D., Augustine, G.J., Fitzpatrick, D., Hall, W.C., LaManita, A.-S., Mooney, R.D., Platt, M.L., and White, L.E. . *Neuroscience, 6th edition*. (Sinauer Associates, 2016).

69 Bear, M. F., Connors, B. W. & Paradiso, M. A. *Neuroscience, Exploring the Brain. 4th Edition*. (Wolters Kluwer, 2016).

70 Kandel, E. R., Schwartz, J.M., Jessell, T.M., Siegelbaum, S.A., and Hudspeth, A.J. *Principles of Neural Sciences. 5th Edition*. (McGraw-Hill, 2013).

71 Kandel, E. R., Koester, J.D., Mack, S.H., and Siegelbaum, S.A. *Principles of Neural Sciences. 6th Edition.*, (McGraw-Hill, 2021).

72 Siegel, A. & Sapru, H. N. *Essential Neuroscience, 2nd edition*. (Wolters Kluwer, 2011).

73 Felix, D. & Künzle, H. Iontophoretic and autoradiographic studies on the role of proline in nervous transmission. *Pflugers Arch* **350**, 135-144, doi:10.1007/bf00586233 (1974).

74 Chantranupong, L. *et al*. Rapid purification and metabolomic profiling of synaptic vesicles from mammalian brain. *Elife* **9**, doi:10.7554/eLife.59699 (2020).

75 Chevreul, E. Sur la composition chimique du bouillon de viandes. *J Pharm Sci Access* **21**, 231-242 (1835).

76 Liebig, J. Kreatin und Kreatinin, Bestandtheile des Harns der Menschen. *Journal für Praktische Chemie* **40**, 288-292 (1847).

77 Wyss, M. & Kaddurah-Daouk, R. Creatine and creatinine metabolism. *Physiol Rev* **80**, 1107-1213, doi:10.1152/physrev.2000.80.3.1107 (2000).

78 Brosnan, J. T. & Brosnan, M. E. Creatine: endogenous metabolite, dietary, and therapeutic supplement. *Annu Rev Nutr* **27**, 241-261, doi:10.1146/annurev.nutr.27.061406.093621 (2007).

79 Wallimann, T., Tokarska-Schlattner, M. & Schlattner, U. The creatine kinase system and pleiotropic effects of creatine. *Amino Acids* **40**, 1271-1296, doi:10.1007/s00726-011-0877-3 (2011).

80 Braissant, O., Henry, H., Béard, E. & Uldry, J. Creatine deficiency syndromes and the importance of creatine synthesis in the brain. *Amino Acids* **40**, 1315-1324, doi:10.1007/s00726-011-0852-z (2011).

81 Ohtsuki, S. *et al*. The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain. *J Cereb Blood Flow Metab* **22**, 1327-1335, doi:10.1097/01.Wcb.0000033966.83623.7d (2002).

82 Braissant, O., Henry, H., Loup, M., Eilers, B. & Bachmann, C. Endogenous synthesis and transport of creatine in the rat brain: an in situ hybridization study. *Molecular brain research* **86**, 193-201, doi:10.1016/s0169-328x(00)00269-2 (2001).

83 Braissant, O., Bachmann, C. & Henry, H. Expression and function of AGAT, GAMT and CT1 in the mammalian brain. *Subcell Biochem* **46**, 67-81, doi:10.1007/978-1-4020-6486-9_4 (2007).
84 Nelson, N. The family of Na+/Cl- neurotransmitter transporters. *J Neurochem* **71**, 1785-1803, doi:10.1046/j.1471-4159.1998.71051785.x (1998).
85 Chen, N. H., Reith, M. E. & Quick, M. W. Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. *Pflugers Arch* **447**, 519-531, doi:10.1007/s00424-003-1064-5 (2004).
86 Höglund, P. J., Adzic, D., Scicluna, S. J., Lindblom, J. & Fredriksson, R. The repertoire of solute carriers of family 6: identification of new human and rodent genes. *Biochem Biophys Res Commun* **336**, 175-189, doi:10.1016/j.bbrc.2005.08.048 (2005).
87 Bröer, S. & Gether, U. The solute carrier 6 family of transporters. *Br J Pharmacol* **167**, 256-278, doi:10.1111/j.1476-5381.2012.01975.x (2012).
88 Iversen, L. Neurotransmitter transporters and their impact on the development of psychopharmacology. *Br J Pharmacol* **147 Suppl 1**, S82-88, doi:10.1038/sj.bjp.0706428 (2006).
89 Bröer, S. The SLC6 orphans are forming a family of amino acid transporters. *Neurochem Int* **48**, 559-567, doi:10.1016/j.neuint.2005.11.021 (2006).
90 Guastella, J., Brecha, N., Weigmann, C., Lester, H. A. & Davidson, N. Cloning, expression, and localization of a rat brain high-affinity glycine transporter. *Proc Natl Acad Sci U S A* **89**, 7189-7193, doi:10.1073/pnas.89.15.7189 (1992).
91 Clark, J. A., Deutch, A. Y., Gallipoli, P. Z. & Amara, S. G. Functional expression and CNS distribution of a beta-alanine-sensitive neuronal GABA transporter. *Neuron* **9**, 337-348, doi:10.1016/0896-6273(92)90172-a (1992).
92 Borden, L. A., Smith, K. E., Hartig, P. R., Branchek, T. A. & Weinshank, R. L. Molecular heterogeneity of the gamma-aminobutyric acid (GABA) transport system. Cloning of two novel high affinity GABA transporters from rat brain. *J Biol Chem* **267**, 21098-21104 (1992).
93 Lopez-Corcuera, B., Liu, Q. R., Mandiyan, S., Nelson, H. & Nelson, N. Expression of a mouse brain cDNA encoding novel gamma-aminobutyric acid transporter. *J Biol Chem* **267**, 17491-17493 (1992).
94 Giros, B., el Mestikawy, S., Bertrand, L. & Caron, M. G. Cloning and functional characterization of a cocaine-sensitive dopamine transporter. *FEBS Lett* **295**, 149-154, doi:10.1016/0014-5793(91)81406-x (1991).
95 Kilty, J. E., Lorang, D. & Amara, S. G. Cloning and expression of a cocaine-sensitive rat dopamine transporter. *Science* **254**, 578-579, doi:10.1126/science.1948035 (1991).
96 Shimada, S. *et al.* Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. *Science* **254**, 576-578, doi:10.1126/science.1948034 (1991).
97 Hoffman, B. J., Mezey, E. & Brownstein, M. J. Cloning of a serotonin transporter affected by antidepressants. *Science* **254**, 579-580, doi:10.1126/science.1948036 (1991).

98 Smith, K. E., Borden, L. A., Hartig, P. R., Branchek, T. & Weinshank, R. L. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. *Neuron* **8**, 927-935, doi:10.1016/0896-6273(92)90207-t (1992).

99 Liu, Q. R., Nelson, H., Mandiyan, S., López-Corcuera, B. & Nelson, N. Cloning and expression of a glycine transporter from mouse brain. *FEBS Lett* **305**, 110-114, doi:10.1016/0014-5793(92)80875-h (1992).

100 Mayser, W., Schloss, P. & Betz, H. Primary structure and functional expression of a choline transporter expressed in the rat nervous system. *FEBS Lett* **305**, 31-36, doi:10.1016/0014-5793(92)80649-2 (1992).

101 Guimbal, C. & Kilimann, M. W. A Na(+)-dependent creatine transporter in rabbit brain, muscle, heart, and kidney. cDNA cloning and functional expression. *J Biol Chem* **268**, 8418-8421 (1993).

102 Gonzalez, A. M. & Uhl, G. R. 'Choline/orphan V8-2-1/creatine transporter' mRNA is expressed in nervous, renal and gastrointestinal systems. *Molecular brain research* **23**, 266-270, doi:10.1016/0169-328x(94)90233-x (1994).

103 Nash, S. R. *et al.* Cloning, pharmacological characterization, and genomic localization of the human creatine transporter. *Recept Channels* **2**, 165-174 (1994).

104 Schloss, P., Mayser, W. & Betz, H. The putative rat choline transporter CHOT1 transports creatine and is highly expressed in neural and muscle-rich tissues. *Biochem Biophys Res Commun* **198**, 637-645, doi:10.1006/bbrc.1994.1093 (1994).

105 Sora, I. *et al.* The cloning and expression of a human creatine transporter. *Biochem Biophys Res Commun* **204**, 419-427, doi:10.1006/bbrc.1994.2475 (1994).

106 Barnwell, L. F., Chaudhuri, G. & Townsel, J. G. Cloning and sequencing of a cDNA encoding a novel member of the human brain GABA/noradrenaline neurotransmitter transporter family. *Gene* **159**, 287-288, doi:10.1016/0378-1119(95)00104-e (1995).

107 Happe, H. K. & Murrin, L. C. In situ hybridization analysis of CHOT1, a creatine transporter, in the rat central nervous system. *J Comp Neurol* **351**, 94-103, doi:10.1002/cne.903510109 (1995).

108 Saltarelli, M. D., Bauman, A. L., Moore, K. R., Bradley, C. C. & Blakely, R. D. Expression of the rat brain creatine transporter in situ and in transfected HeLa cells. *Dev Neurosci* **18**, 524-534, doi:10.1159/000111450 (1996).

109 Mak, C. S. *et al.* Immunohistochemical localisation of the creatine transporter in the rat brain. *Neuroscience* **163**, 571-585, doi:10.1016/j.neuroscience.2009.06.065 (2009).

110 Speer, O. *et al.* Creatine transporters: a reappraisal. *Mol Cell Biochem* **256**, 407-424, doi:10.1023/b:mcbi.0000009886.98508.e7 (2004).

111 Lowe, M. T., Faull, R. L., Christie, D. L. & Waldvogel, H. J. Distribution of the creatine transporter throughout the human brain reveals a spectrum of creatine

transporter immunoreactivity. *J Comp Neurol* **523**, 699-725, doi:10.1002/cne.23667 (2015).

112 Salomons, G. S. *et al.* X-linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome. *Am J Hum Genet* **68**, 1497-1500, doi:10.1086/320595 (2001).

113 Mancardi, M. M. *et al.* Severe epilepsy in X-linked creatine transporter defect (CRTR-D). *Epilepsia* **48**, 1211-1213, doi:10.1111/j.1528-1167.2007.01148.x (2007).

114 Battini, R. *et al.* Language disorder with mild intellectual disability in a child affected by a novel mutation of SLC6A8 gene. *Mol Genet Metab* **102**, 153-156, doi:10.1016/j.ymgme.2010.11.005 (2011).

115 Rosenberg, E. H. *et al.* High prevalence of SLC6A8 deficiency in X-linked mental retardation. *Am J Hum Genet* **75**, 97-105, doi:10.1086/422102 (2004).

116 Newmeyer, A., Cecil, K. M., Schapiro, M., Clark, J. F. & Degrauw, T. J. Incidence of brain creatine transporter deficiency in males with developmental delay referred for brain magnetic resonance imaging. *J Dev Behav Pediatr* **26**, 276-282, doi:10.1097/00004703-200508000-00003 (2005).

117 Clark, A. J. *et al.* X-linked creatine transporter (SLC6A8) mutations in about 1% of males with mental retardation of unknown etiology. *Hum Genet* **119**, 604-610, doi:10.1007/s00439-006-0162-9 (2006).

118 Lion-François, L. *et al.* High frequency of creatine deficiency syndromes in patients with unexplained mental retardation. *Neurology* **67**, 1713-1714, doi:10.1212/01.wnl.0000239153.39710.81 (2006).

119 Arias, A. *et al.* Creatine transporter deficiency: prevalence among patients with mental retardation and pitfalls in metabolite screening. *Clin Biochem* **40**, 1328-1331, doi:10.1016/j.clinbiochem.2007.07.010 (2007).

120 Puusepp, H. *et al.* The screening of SLC6A8 deficiency among Estonian families with X-linked mental retardation. *J Inherit Metab Dis* **33**, S5-11, doi:10.1007/s10545-008-1063-y (2010).

121 Cheillan, D. *et al.* Screening for primary creatine deficiencies in French patients with unexplained neurological symptoms. *Orphanet J Rare Dis* **7**, 96, doi:10.1186/1750-1172-7-96 (2012).

122 van de Kamp, J. M., Mancini, G. M. & Salomons, G. S. X-linked creatine transporter deficiency: clinical aspects and pathophysiology. *J Inherit Metab Dis* **37**, 715-733, doi:10.1007/s10545-014-9713-8 (2014).

123 Joncquel-Chevalier Curt, M. *et al.* Creatine biosynthesis and transport in health and disease. *Biochimie* **119**, 146-165, doi:10.1016/j.biochi.2015.10.022 (2015).

124 DesRoches, C. L. *et al.* Estimated carrier frequency of creatine transporter deficiency in females in the general population using functional characterization of novel missense variants in the SLC6A8 gene. *Gene* **565**, 187-191, doi:10.1016/j.gene.2015.04.011 (2015).

125 Skelton, M. R. *et al.* Creatine transporter (CrT; Slc6a8) knockout mice as a model of human CrT deficiency. *PLoS One* **6**, e16187, doi:10.1371/journal.pone.0016187 (2011).

126 Kurosawa, Y. *et al.* Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency. *J Clin Invest* **122**, 2837-2846, doi:10.1172/jci59373 (2012).
127 Baroncelli, L. *et al.* A mouse model for creatine transporter deficiency reveals early onset cognitive impairment and neuropathology associated with brain aging. *Hum Mol Genet* **25**, 4186-4200, doi:10.1093/hmg/ddw252 (2016).
128 Udobi, K. C. *et al.* Cognitive deficits and increases in creatine precursors in a brain-specific knockout of the creatine transporter gene Slc6a8. *Genes Brain Behav* **17**, e12461, doi:10.1111/gbb.12461 (2018).
129 Molinaro, A. *et al.* A Nervous System-Specific Model of Creatine Transporter Deficiency Recapitulates the Cognitive Endophenotype of the Disease: a Longitudinal Study. *Sci Rep* **9**, 62, doi:10.1038/s41598-018-37303-1 (2019).
130 Abdulla, Z. I. *et al.* Deletion of the Creatine Transporter (Slc6a8) in Dopaminergic Neurons Leads to Hyperactivity in Mice. *J Mol Neurosci* **70**, 102-111, doi:10.1007/s12031-019-01405-w (2020).
131 Stöckler, S. *et al.* Creatine deficiency in the brain: a new, treatable inborn error of metabolism. *Pediatr Res* **36**, 409-413, doi:10.1203/00006450-199409000-00023 (1994).
132 Bianchi, M. C. *et al.* Reversible brain creatine deficiency in two sisters with normal blood creatine level. *Ann Neurol* **47**, 511-513 (2000).
133 Item, C. B. *et al.* Arginine:glycine amidinotransferase deficiency: the third inborn error of creatine metabolism in humans. *Am J Hum Genet* **69**, 1127-1133, doi:10.1086/323765 (2001).
134 Stockler-Ipsiroglu, S. *et al.* Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring. *Mol Genet Metab* **111**, 16-25, doi:10.1016/j.ymgme.2013.10.018 (2014).
135 Stockler-Ipsiroglu, S. *et al.* Arginine:glycine amidinotransferase (AGAT) deficiency: Clinical features and long term outcomes in 16 patients diagnosed worldwide. *Mol Genet Metab* **116**, 252-259, doi:10.1016/j.ymgme.2015.10.003 (2015).
136 Khan, A., Tian, L., Zhang, C., Yuan, K. & Xu, S. Genetic diversity and natural selection footprints of the glycine amidinotransferase gene in various human populations. *Sci Rep* **6**, 18755, doi:10.1038/srep18755 (2016).
137 Fons, C. & Campistol, J. Creatine Defects and Central Nervous System. *Semin Pediatr Neurol* **23**, 285-289, doi:10.1016/j.spen.2016.11.003 (2016).
138 Whittaker, V. P., Michaelson, I. A. & Kirkland, R. J. The separation of synaptic vesicles from nerve-ending particles ('synaptosomes'). *Biochem J* **90**, 293-303, doi:10.1042/bj0900293 (1964).
139 Nagy, A., Baker, R. R., Morris, S. J. & Whittaker, V. P. The preparation and characterization of synaptic vesicles of high purity. *Brain Res* **109**, 285-309, doi:10.1016/0006-8993(76)90531-x (1976).
140 Matthew, W. D., Tsavaler, L. & Reichardt, L. F. Identification of a synaptic vesicle-specific membrane protein with a wide distribution in neuronal and

neurosecretory tissue. *J Cell Biol* **91**, 257-269, doi:10.1083/jcb.91.1.257 (1981).

141 De Camilli, P., Harris, S. M., Jr., Huttner, W. B. & Greengard, P. Synapsin I (Protein I), a nerve terminal-specific phosphoprotein. II. Its specific association with synaptic vesicles demonstrated by immunocytochemistry in agarose-embedded synaptosomes. *J Cell Biol* **96**, 1355-1373, doi:10.1083/jcb.96.5.1355 (1983).

142 Huttner, W. B., Schiebler, W., Greengard, P. & De Camilli, P. Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. *J Cell Biol* **96**, 1374-1388, doi:10.1083/jcb.96.5.1374 (1983).

143 Burger, P. M. *et al.* Synaptic vesicles immunoisolated from rat cerebral cortex contain high levels of glutamate. *Neuron* **3**, 715-720, doi:10.1016/0896-6273(89)90240-7 (1989).

144 Burger, P. M. *et al.* GABA and glycine in synaptic vesicles: storage and transport characteristics. *Neuron* **7**, 287-293, doi:10.1016/0896-6273(91)90267-4 (1991).

145 Maycox, P. R., Link, E., Reetz, A., Morris, S. A. & Jahn, R. Clathrin-coated vesicles in nervous tissue are involved primarily in synaptic vesicle recycling. *J Cell Biol* **118**, 1379-1388, doi:10.1083/jcb.118.6.1379 (1992).

146 Jahn, R., Schiebler, W., Ouimet, C. & Greengard, P. A 38,000-dalton membrane protein (p38) present in synaptic vesicles. *Proc Natl Acad Sci U S A* **82**, 4137-4141, doi:10.1073/pnas.82.12.4137 (1985).

147 Wiedenmann, B. & Franke, W. W. Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. *Cell* **41**, 1017-1028, doi:10.1016/s0092-8674(85)80082-9 (1985).

148 Leube, R. E. *et al.* Synaptophysin: molecular organization and mRNA expression as determined from cloned cDNA. *Embo j* **6**, 3261-3268, doi:10.1002/j.1460-2075.1987.tb02644.x (1987).

149 Südhof, T. C., Lottspeich, F., Greengard, P., Mehl, E. & Jahn, R. A synaptic vesicle protein with a novel cytoplasmic domain and four transmembrane regions. *Science* **238**, 1142-1144, doi:10.1126/science.3120313 (1987).

150 Jahn, R. & Südhof, T. C. Synaptic vesicles and exocytosis. *Annu Rev Neurosci* **17**, 219-246, doi:10.1146/annurev.ne.17.030194.001251 (1994).

151 Martineau, M. *et al.* Storage and uptake of D-serine into astrocytic synaptic-like vesicles specify gliotransmission. *J Neurosci* **33**, 3413-3423, doi:10.1523/JNEUROSCI.3497-12.2013 (2013).

152 Bradberry, M. M. *et al.* Rapid and Gentle Immunopurification of Brain Synaptic Vesicles. *J Neurosci* **42**, 3512-3522, doi:10.1523/jneurosci.2521-21.2022 (2022).

153 Ahmed, S., Holt, M., Riedel, D. & Jahn, R. Small-scale isolation of synaptic vesicles from mammalian brain. *Nat Protoc* **8**, 998-1009, doi:10.1038/nprot.2013.053 (2013).

154 Takamori, S. *et al.* Molecular anatomy of a trafficking organelle. *Cell* **127**, 831-846, doi:10.1016/j.cell.2006.10.030 (2006).
155 Geppert, M. *et al.* Synaptotagmin I: a major Ca2+ sensor for transmitter release at a central synapse. *Cell* **79**, 717-727, doi:10.1016/0092-8674(94)90556-8 (1994).
156 Link, E. *et al.* Tetanus toxin action: inhibition of neurotransmitter release linked to synaptobrevin proteolysis. *Biochem Biophys Res Commun* **189**, 1017-1023, doi:10.1016/0006-291x(92)92305-h (1992).
157 Schiavo, G. *et al.* Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. *Nature* **359**, 832-835, doi:10.1038/359832a0 (1992).
158 Bajjalieh, S. M., Peterson, K., Shinghal, R. & Scheller, R. H. SV2, a brain synaptic vesicle protein homologous to bacterial transporters. *Science* **257**, 1271-1273, doi:10.1126/science.1519064 (1992).
159 Cidon, S. & Sihra, T. S. Characterization of a H+-ATPase in rat brain synaptic vesicles. Coupling to L-glutamate transport. *J Biol Chem* **264**, 8281-8288 (1989).
160 Takamori, S., Rhee, J. S., Rosenmund, C. & Jahn, R. Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons. *Nature* **407**, 189-194, doi:10.1038/35025070 (2000).
161 McIntire, S. L., Reimer, R. J., Schuske, K., Edwards, R. H. & Jorgensen, E. M. Identification and characterization of the vesicular GABA transporter. *Nature* **389**, 870-876, doi:10.1038/39908 (1997).
162 Kunii, M. *et al.* SNAP23 deficiency causes severe brain dysplasia through the loss of radial glial cell polarity. *J Cell Biol* **220**, doi:10.1083/jcb.201910080 (2021).
163 Ravichandran, V., Chawla, A. & Roche, P. A. Identification of a novel syntaxin- and synaptobrevin/VAMP-binding protein, SNAP-23, expressed in non-neuronal tissues. *J Biol Chem* **271**, 13300-13303, doi:10.1074/jbc.271.23.13300 (1996).
164 Suh, Y. H. *et al.* A neuronal role for SNAP-23 in postsynaptic glutamate receptor trafficking. *Nature Neuroscience* **13**, 338-U316, doi:10.1038/nn.2488 (2010).
165 Woods, D. F. & Bryant, P. J. The discs-large tumor suppressor gene of Drosophila encodes a guanylate kinase homolog localized at septate junctions. *Cell* **66**, 451-464, doi:10.1016/0092-8674(81)90009-x (1991).
166 Cho, K. O., Hunt, C. A. & Kennedy, M. B. The rat brain postsynaptic density fraction contains a homolog of the Drosophila discs-large tumor suppressor protein. *Neuron* **9**, 929-942, doi:10.1016/0896-6273(92)90245-9 (1992).
167 Nakamura, N. *et al.* Characterization of a cis-Golgi matrix protein, GM130. *J Cell Biol* **131**, 1715-1726, doi:10.1083/jcb.131.6.1715 (1995).
168 Griffith, K. J. *et al.* Molecular cloning of a novel 97-kd Golgi complex autoantigen associated with Sjögren's syndrome. *Arthritis Rheum* **40**, 1693-1702, doi:10.1002/art.1780400920 (1997).

169 Mu, F. T. *et al.* EEA1, an early endosome-associated protein. EEA1 is a conserved alpha-helical peripheral membrane protein flanked by cysteine "fingers" and contains a calmodulin-binding IQ motif. *J Biol Chem* **270**, 13503-13511, doi:10.1074/jbc.270.22.13503 (1995).

170 Tie, C., Zhang, D. W., Chen, H. X., Song, S. L. & Zhang, X. X. Study of the electrical connection mechanism of sheathless interface for capillary electrophoresis-electrospray ionization-mass spectrometry. *J Mass Spectrom* **47**, 1429-1434, doi:10.1002/jms.3077 (2012).

171 Meyer, H. S. *et al.* Inhibitory interneurons in a cortical column form hot zones of inhibition in layers 2 and 5A. *Proc Natl Acad Sci U S A* **108**, 16807-16812, doi:10.1073/pnas.1113648108 (2011).

172 Olbrich, H. G. & Braak, H. Ratio of pyramidal cells versus non-pyramidal cells in sector CA1 of the human Ammon's horn. *Anat Embryol (Berl)* **173**, 105-110, doi:10.1007/bf00707308 (1985).

173 Tremblay, R., Lee, S. & Rudy, B. GABAergic Interneurons in the Neocortex: From Cellular Properties to Circuits. *Neuron* **91**, 260-292, doi:10.1016/j.neuron.2016.06.033 (2016).

174 Li, X. *et al.* Generation of a whole-brain atlas for the cholinergic system and mesoscopic projectome analysis of basal forebrain cholinergic neurons. *Proc Natl Acad Sci U S A* **115**, 415-420, doi:10.1073/pnas.1703601115 (2018).

175 Herculano-Houzel, S., Mota, B. & Lent, R. Cellular scaling rules for rodent brains. *Proc Natl Acad Sci U S A* **103**, 12138-12143, doi:10.1073/pnas.0604911103 (2006).

176 Ishimura, K. *et al.* Quantitative analysis of the distribution of serotonin-immunoreactive cell bodies in the mouse brain. *Neurosci Lett* **91**, 265-270, doi:10.1016/0304-3940(88)90691-x (1988).

177 Egashira, Y. *et al.* Unique pH dynamics in GABAergic synaptic vesicles illuminates the mechanism and kinetics of GABA loading. *Proc Natl Acad Sci U S A* **113**, 10702-10707, doi:10.1073/pnas.1604527113 (2016).

178 Mani, M. & Ryan, T. A. Live imaging of synaptic vesicle release and retrieval in dopaminergic neurons. *Front Neural Circuits* **3**, 3, doi:10.3389/neuro.04.003.2009 (2009).

179 Egashira, Y., Takase, M. & Takamori, S. Monitoring of vacuolar-type H+ ATPase-mediated proton influx into synaptic vesicles. *J Neurosci* **35**, 3701-3710, doi:10.1523/jneurosci.4160-14.2015 (2015).

180 Qian, C. *et al.* Localization, proteomics, and metabolite profiling reveal a putative vesicular transporter for UDP-glucose. *Elife* **10**, doi:10.7554/eLife.65417 (2021).

181 Schenck, S., Wojcik, S. M., Brose, N. & Takamori, S. A chloride conductance in VGLUT1 underlies maximal glutamate loading into synaptic vesicles. *Nat Neurosci* **12**, 156-162, doi:10.1038/nn.2248 (2009).

182 Duran-Trio, L. *et al.* A new rat model of creatine transporter deficiency reveals behavioral disorder and altered brain metabolism. *Sci Rep* **11**, 1636, doi:10.1038/s41598-020-80824-x (2021).

183 Stockebrand, M. *et al.* A Mouse Model of Creatine Transporter Deficiency Reveals Impaired Motor Function and Muscle Energy Metabolism. *Front Physiol* **9**, 773, doi:10.3389/fphys.2018.00773 (2018).

184 Guthmiller, P., Van Pilsum, J. F., Boen, J. R. & McGuire, D. M. Cloning and sequencing of rat kidney L-arginine:glycine amidinotransferase. Studies on the mechanism of regulation by growth hormone and creatine. *J Biol Chem* **269**, 17556-17560 (1994).

185 Skarnes, W. C. *et al.* A conditional knockout resource for the genome-wide study of mouse gene function. *Nature* **474**, 337-342, doi:10.1038/nature10163 (2011).

186 Kolodziej, P. A. & Young, R. A. Epitope tagging and protein surveillance. *Methods Enzymol* **194**, 508-519, doi:10.1016/0076-6879(91)94038-e (1991).

187 Ryan, M. D., King, A. M. & Thomas, G. P. Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. *J Gen Virol* **72 (Pt 11)**, 2727-2732, doi:10.1099/0022-1317-72-11-2727 (1991).

188 Ahier, A. & Jarriault, S. Simultaneous expression of multiple proteins under a single promoter in Caenorhabditis elegans via a versatile 2A-based toolkit. *Genetics* **196**, 605-613, doi:10.1534/genetics.113.160846 (2014).

189 Daniels, R. W., Rossano, A. J., Macleod, G. T. & Ganetzky, B. Expression of multiple transgenes from a single construct using viral 2A peptides in Drosophila. *PLoS One* **9**, e100637, doi:10.1371/journal.pone.0100637 (2014).

190 Sauer, B. & Henderson, N. Cre-stimulated recombination at loxP-containing DNA sequences placed into the mammalian genome. *Nucleic Acids Res* **17**, 147-161, doi:10.1093/nar/17.1.147 (1989).

191 Gu, H., Zou, Y. R. & Rajewsky, K. Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. *Cell* **73**, 1155-1164, doi:10.1016/0092-8674(93)90644-6 (1993).

192 Feil, R., Wagner, J., Metzger, D. & Chambon, P. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. *Biochem Biophys Res Commun* **237**, 752-757, doi:10.1006/bbrc.1997.7124 (1997).

193 Indra, A. K. *et al.* Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. *Nucleic Acids Res* **27**, 4324-4327, doi:10.1093/nar/27.22.4324 (1999).

194 Hamberger, A., Chiang, G. H., Sandoval, E. & Cotman, C. W. Glutamate as a CNS transmitter. II. Regulation of synthesis in the releasable pool. *Brain Res* **168**, 531-541, doi:10.1016/0006-8993(79)90307-x (1979).

195 Hamberger, A. C., Chiang, G. H., Nylen, E. S., Scheff, S. W. & Cotman, C. W. Glutamate as a CNS transmitter. I. Evaluation of glucose and glutamine as precursors for the synthesis of preferentially released glutamate. *Brain Res* **168**, 513-530, doi:10.1016/0006-8993(79)90306-8 (1979).

196 McBride, W. J., Flint, R. S., Ciancone, M. T. & Murphy, J. M. In vitro release of endogenous monoamines and amino acids from several CNS regions of the rat. *Neurochem Res* **8**, 245-257, doi:10.1007/BF00963924 (1983).
197 Nadler, J. V., White, W. F., Vaca, K. W., Redburn, D. A. & Cotman, C. W. Characterization of putative amino acid transmitter release from slices of rat dentate gyrus. *J Neurochem* **29**, 279-290, doi:10.1111/j.1471-4159.1977.tb09620.x (1977).
198 Keith, R. A., Horn, M. B., Piser, T. M. & Mangano, T. J. Effects of stimulus intensity on the inhibition by omega-conotoxin GVIA and neomycin of K(+_-evoked [3H]norepinephrine release from hippocampal brain slices and synaptosomal calcium influx. *Biochem Pharmacol* **45**, 165-171, doi:10.1016/0006-2952(93)90389-e (1993).
199 Eliseeva, Z. V. & Durinian, R. A. [Projections of the somatosensory areas of the cerebral cortex into the thalamic nuclei]. *Biull Eksp Biol Med* **80**, 113-117 (1975).
200 Yamawaki, N., Raineri Tapies, M. G., Stults, A., Smith, G. A. & Shepherd, G. M. Circuit organization of the excitatory sensorimotor loop through hand/forelimb S1 and M1. *Elife* **10**, doi:10.7554/eLife.66836 (2021).
201 Scala, F. *et al.* Layer 4 of mouse neocortex differs in cell types and circuit organization between sensory areas. *Nat Commun* **10**, 4174, doi:10.1038/s41467-019-12058-z (2019).
202 Stumpf, A. *et al.* Cannabinoid type 2 receptors mediate a cell type-specific self-inhibition in cortical neurons. *Neuropharmacology* **139**, 217-225, doi:10.1016/j.neuropharm.2018.07.020 (2018).
203 Gulyassy, P. *et al.* Proteomic comparison of different synaptosome preparation procedures. *Amino Acids* **52**, 1529-1543, doi:10.1007/s00726-020-02912-6 (2020).
204 Antonucci, F. *et al.* SNAP-25, a Known Presynaptic Protein with Emerging Postsynaptic Functions. *Front Synaptic Neurosci* **8**, 7, doi:10.3389/fnsyn.2016.00007 (2016).
205 Cserép, C. *et al.* NMDA receptors in GABAergic synapses during postnatal development. *PLoS One* **7**, e37753, doi:10.1371/journal.pone.0037753 (2012).
206 Cameron, R., Klein, L., Shyjan, A. W., Rakic, P. & Levenson, R. Neurons and astroglia express distinct subsets of Na,K-ATPase alpha and beta subunits. *Brain Res Mol Brain Res* **21**, 333-343, doi:10.1016/0169-328x(94)90264-x (1994).
207 Mersel, M., Lelong, I., Hindelang, C., Sarlieve, L. & Vincendon, G. Isolation of plasma membranes from neurons grown in primary culture. *Anal Biochem* **166**, 246-252, doi:10.1016/0003-2697(87)90571-9 (1987).
208 Sun, G. Y., Huang, H. M., Kelleher, J. A., Stubbs, E. B., Jr. & Sun, A. Y. Marker enzymes, phospholipids and acyl group composition of a somal plasma membrane fraction isolated from rat cerebral cortex: a comparison with microsomes and synaptic plasma membranes. *Neurochem Int* **12**, 69-77, doi:10.1016/0197-0186(88)90150-7 (1988).

209 Schrimpf, S. P. *et al.* Proteomic analysis of synaptosomes using isotope-coded affinity tags and mass spectrometry. *Proteomics* **5**, 2531-2541, doi:10.1002/pmic.200401198 (2005).

210 Fykse, E. M. & Fonnum, F. Uptake of Gamma-Aminobutyric Acid by a Synaptic Vesicle Fraction Isolated from Rat-Brain. *Journal of Neurochemistry* **50**, 1237-1242, doi:DOI 10.1111/j.1471-4159.1988.tb10599.x (1988).

211 Bellocchio, E. E., Reimer, R. J., Fremeau, R. T., Jr. & Edwards, R. H. Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. *Science* **289**, 957-960, doi:10.1126/science.289.5481.957 (2000).

212 Oja, S. S. & Saransaari, P. *Taurine and neurotransmission. In Taurine in Health and Disease, Ed (El Idrissi, A., and L'Amoreaux, W.).* (Trivandrum, Kerala, 2012).

213 D'Aniello, S., Somorjai, I., Garcia-Fernàndez, J., Topo, E. & D'Aniello, A. D-Aspartic acid is a novel endogenous neurotransmitter. *Faseb j* **25**, 1014-1027, doi:10.1096/fj.10-168492 (2011).

214 Abe, K. & Kimura, H. The possible role of hydrogen sulfide as an endogenous neuromodulator. *J Neurosci* **16**, 1066-1071, doi:10.1523/jneurosci.16-03-01066.1996 (1996).

215 Reis, D. J. & Regunathan, S. Is agmatine a novel neurotransmitter in brain? *Trends Pharmacol Sci* **21**, 187-193, doi:10.1016/s0165-6147(00)01460-7 (2000).

216 Misu, Y., Goshima, Y. & Miyamae, T. Is DOPA a neurotransmitter? *Trends Pharmacol Sci* **23**, 262-268, doi:10.1016/s0165-6147(02)02013-8 (2002).

217 Balthazart, J. & Ball, G. F. Is brain estradiol a hormone or a neurotransmitter? *Trends Neurosci* **29**, 241-249, doi:10.1016/j.tins.2006.03.004 (2006).

218 Tiedje, K. E., Stevens, K., Barnes, S. & Weaver, D. F. Beta-alanine as a small molecule neurotransmitter. *Neurochem Int* **57**, 177-188, doi:10.1016/j.neuint.2010.06.001 (2010).

219 Du, J. *et al.* Protons are a neurotransmitter that regulates synaptic plasticity in the lateral amygdala. *Proc Natl Acad Sci U S A* **111**, 8961-8966, doi:10.1073/pnas.1407018111 (2014).

220 Almeida, L. S., Salomons, G. S., Hogenboom, F., Jakobs, C. & Schoffelmeer, A. N. Exocytotic release of creatine in rat brain. *Synapse* **60**, 118-123, doi:10.1002/syn.20280 (2006).

221 Peral, M. J., Vazquez-Carretero, M. D. & Ilundain, A. A. Na+/Cl-/CREATINE TRANSPORTER ACTIVITY AND EXPRESSION IN RAT BRAIN SYNAPTOSOMES. *Neuroscience* **165**, 53-60, doi:10.1016/j.neuroscience.2009.10.001 (2010).

222 Cooper, J. R., Bloom, F. E. & Roth, R. H. *The Biochemical Basis of Neuropharmacology p.2.* (Oxford University Press, 2003).

223 Squire, L., Berg, D., Bloom, F.E., du Lac, S., Ghosh, A., and Spitzer, N.C. *Fundamental Neuroscience, 4th edition*. (Elsevier, 2012).

224 Robinson, J. D. *Mechanisms of Synaptic Transmission. Bridging the Gaps*. (Oxford University Press, 2001).

225 Barañano, D. E., Ferris, C. D. & Snyder, S. H. Atypical neural messengers. *Trends Neurosci* **24**, 99-106, doi:10.1016/s0166-2236(00)01716-1 (2001).
226 Brown, D. A. & Scholfield, C. N. Depolarization of neurones in the isolated olfactory cortex of the guinea-pig by gamma-aminobutyric acid. *Br J Pharmacol* **65**, 339-345, doi:10.1111/j.1476-5381.1979.tb07835.x (1979).
227 Pringle, A. K., Gardner, C. R. & Walker, R. J. Reduction of cerebellar GABAA responses by interleukin-1 (IL-1) through an indomethacin insensitive mechanism. *Neuropharmacology* **35**, 147-152, doi:10.1016/0028-3908(95)00161-1 (1996).
228 Osmanović, S. S. & Shefner, S. A. gamma-Aminobutyric acid responses in rat locus coeruleus neurones in vitro: a current-clamp and voltage-clamp study. *J Physiol* **421**, 151-170, doi:10.1113/jphysiol.1990.sp017938 (1990).
229 Akaike, A., Ohno, Y., Sasa, M. & Takaori, S. Excitatory and inhibitory effects of dopamine on neuronal activity of the caudate nucleus neurons in vitro. *Brain Res* **418**, 262-272, doi:10.1016/0006-8993(87)90094-1 (1987).
230 Cole, A. E., ffench-Mullen, J. M. & Fisher, R. S. Fade of the response to prolonged glutamate application in the rat hippocampal slice. *Synapse* **4**, 11-18, doi:10.1002/syn.890040103 (1989).
231 Beck, S. G. & Goldfarb, J. Serotonin produces a reversible concentration dependent decrease of population spikes in rat hippocampal slices. *Life Sci* **36**, 557-563, doi:10.1016/0024-3205(85)90637-x (1985).
232 Reynolds, J. N., Baskys, A. & Carlen, P. L. The effects of serotonin on N-methyl-D-aspartate and synaptically evoked depolarizations in rat neocortical neurons. *Brain Res* **456**, 286-292, doi:10.1016/0006-8993(88)90230-2 (1988).
233 Mendiguren, A., Aostri, E., Alberdi, E., Pérez-Samartín, A. & Pineda, J. Functional characterization of cannabidiol effect on the serotonergic neurons of the dorsal raphe nucleus in rat brain slices. *Front Pharmacol* **13**, 956886, doi:10.3389/fphar.2022.956886 (2022).
234 Xie, D. J. *et al.* Identification of 5-HT receptor subtypes enhancing inhibitory transmission in the rat spinal dorsal horn in vitro. *Mol Pain* **8**, 58, doi:10.1186/1744-8069-8-58 (2012).
235 Gorelova, N. & Reiner, P. B. Role of the afterhyperpolarization in control of discharge properties of septal cholinergic neurons in vitro. *J Neurophysiol* **75**, 695-706, doi:10.1152/jn.1996.75.2.695 (1996).
236 Okuhara, D. Y. & Beck, S. G. 5-HT1A receptor linked to inward-rectifying potassium current in hippocampal CA3 pyramidal cells. *J Neurophysiol* **71**, 2161-2167, doi:10.1152/jn.1994.71.6.2161 (1994).
237 Sizer, A. R., Kilpatrick, G. J. & Roberts, M. H. A post-synaptic depressant modulatory action of 5-hydroxytryptamine on excitatory amino acid responses in rat entorhinal cortex in vitro. *Neuropharmacology* **31**, 531-539, doi:10.1016/0028-3908(92)90184-q (1992).
238 De Deyn, P. P. & Macdonald, R. L. Guanidino compounds that are increased in cerebrospinal fluid and brain of uremic patients inhibit GABA and glycine

responses on mouse neurons in cell culture. *Ann Neurol* **28**, 627-633, doi:10.1002/ana.410280505 (1990).

239 De Deyn, P. P., D'Hooge, R., Van Bogaert, P. P. & Marescau, B. Endogenous guanidino compounds as uremic neurotoxins. *Kidney Int Suppl* **78**, S77-83, doi:10.1046/j.1523-1755.2001.59780077.x (2001).

240 Neu, A. *et al.* Activation of GABA(A) receptors by guanidinoacetate: a novel pathophysiological mechanism. *Neurobiol Dis* **11**, 298-307, doi:10.1006/nbdi.2002.0547 (2002).

241 Koga, Y. *et al.* Brain creatine functions to attenuate acute stress responses through GABAnergic system in chicks. *Neuroscience* **132**, 65-71, doi:10.1016/j.neuroscience.2005.01.004 (2005).

242 Royes, L. F. *et al.* Neuromodulatory effect of creatine on extracellular action potentials in rat hippocampus: role of NMDA receptors. *Neurochem Int* **53**, 33-37, doi:10.1016/j.neuint.2008.04.008 (2008).

243 Braissant, O. & Henry, H. AGAT, GAMT and SLC6A8 distribution in the central nervous system, in relation to creatine deficiency syndromes: a review. *J Inherit Metab Dis* **31**, 230-239, doi:10.1007/s10545-008-0826-9 (2008).

244 Braissant, O., Béard, E., Torrent, C. & Henry, H. Dissociation of AGAT, GAMT and SLC6A8 in CNS: relevance to creatine deficiency syndromes. *Neurobiol Dis* **37**, 423-433, doi:10.1016/j.nbd.2009.10.022 (2010).

245 Dunbar, M., Jaggumantri, S., Sargent, M., Stockler-Ipsiroglu, S. & van Karnebeek, C. D. Treatment of X-linked creatine transporter (SLC6A8) deficiency: systematic review of the literature and three new cases. *Mol Genet Metab* **112**, 259-274, doi:10.1016/j.ymgme.2014.05.011 (2014).

246 Mercimek-Mahmutoglu, S. *et al.* Treatment of intractable epilepsy in a female with SLC6A8 deficiency. *Mol Genet Metab* **101**, 409-412, doi:10.1016/j.ymgme.2010.08.016 (2010).

247 Gerbatin, R. R. *et al.* Delayed creatine supplementation counteracts reduction of GABAergic function and protects against seizures susceptibility after traumatic brain injury in rats. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* **92**, 328-338, doi:10.1016/j.pnpbp.2019.02.004 (2019).

248 Braissant, O. Creatine and guanidinoacetate transport at blood-brain and blood-cerebrospinal fluid barriers. *J Inherit Metab Dis* **35**, 655-664, doi:10.1007/s10545-011-9433-2 (2012).

249 Brosnan, M. E. & Brosnan, J. T. The role of dietary creatine. *Amino Acids* **48**, 1785-1791, doi:10.1007/s00726-016-2188-1 (2016).

250 Watanabe, A., Kato, N. & Kato, T. Effects of creatine on mental fatigue and cerebral hemoglobin oxygenation. *Neurosci Res* **42**, 279-285, doi:10.1016/s0168-0102(02)00007-x (2002).

251 Rae, C., Digney, A. L., McEwan, S. R. & Bates, T. C. Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial. *Proc Biol Sci* **270**, 2147-2150, doi:10.1098/rspb.2003.2492 (2003).

252 McMorris, T. *et al.* Effect of creatine supplementation and sleep deprivation, with mild exercise, on cognitive and psychomotor performance, mood state, and plasma concentrations of catecholamines and cortisol. *Psychopharmacology (Berl)* **185**, 93-103, doi:10.1007/s00213-005-0269-z (2006).

253 McMorris, T. *et al.* Creatine supplementation, sleep deprivation, cortisol, melatonin and behavior. *Physiol Behav* **90**, 21-28, doi:10.1016/j.physbeh.2006.08.024 (2007).

254 Rae, C. D. & Bröer, S. Creatine as a booster for human brain function. How might it work? *Neurochem Int* **89**, 249-259, doi:10.1016/j.neuint.2015.08.010 (2015).

255 Wallimann, T. & Harris, R. Creatine: a miserable life without it. *Amino Acids* **48**, 1739-1750, doi:10.1007/s00726-016-2297-x (2016).

256 Andreassen, O. A. *et al.* Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. *Neurobiol Dis* **8**, 479-491, doi:10.1006/nbdi.2001.0406 (2001).

257 Andres, R. H. *et al.* Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue. *Neuroscience* **133**, 701-713, doi:10.1016/j.neuroscience.2005.03.004 (2005).

258 Paxinos, G. & Franklin., K. B. J. *Paxinos and Franklin's the mouse brain in stereotaxic coordinates 4th edition*. (Elsevier/Academic Press, 2013).

259 Booth, R. F. G. & Clark, J. B. Rapid Method for Preparation of Relatively Pure Metabolically Competent Synaptosomes from Rat-Brain. *Biochemical Journal* **176**, 365-&, doi:DOI 10.1042/bj1760365 (1978).

260 Hell, J. W., Maycox, P. R., Stadler, H. & Jahn, R. Uptake of GABA by rat brain synaptic vesicles isolated by a new procedure. *Embo j* **7**, 3023-3029, doi:10.1002/j.1460-2075.1988.tb03166.x (1988).


a
Glutamate
7*10^6
0
148.06/84.04
GABA
2.5*10^6
0
104.07/87.04
Acetylcholine
2*10^6
0
146.118/87.044
IgG
Syp
Syp (RT)
5-HT
30000
0
117.1/160.08
Creatine
2*10^5
0
132.0/90
Choline
5000
0
104.11/58
5 6 7 8 9 10 11
time (min)
b
Glutamate
c
GABA
d
Acetylcholine
pmol/µg Syp
***
WT IgG
WT Syp
WT Syp (RT)
e
5-HT
f
Creatine
g
Alanine
ns


a
Wild type allele of Slc6a8
E1
Targeting vector
for Slc6a8 KO mice
ATG
1.4 kb
E1
1.35 kb
5'UTR iCreERT2 WPRE-pA
CRISPER/Cas9
b
WT-IgG
WT-Syp
6a8 KO-IgG
6a8 KO-Syp
Creatine
3*10^5
0
time (min)
c
Creatine
d
Glutamate
e
GABA
f
Acetylcholine
g
5-HT
h
Alanine
pmol/µg Syp
***
ns
WT IgG
WT Syp
6a8 KO IgG
6a8 KO Syp
6a8KO Syp


a
Agat+/+
Agat+/-
Agat-/-
IgG
Syp
Creatine
5*10^5
0
5 6 7 8 9 10 11
b
Creatine
c
Glutamate
d
GABA
e
ACh
f
5-HT
g
Alanine
pmol/µg Syp
IgG
Syp
Agat
+/+
+/-
-/-
***
**


a
Wild type allele of *Slc6a8*
E1
CRISPER/Cas9
Targeting vector
for *Slc6a8* KI mice
3*HA
T2A
CreERT2
stop codon
b
Olfactory bulb
c
Pir
d
M
Pir
e
M
Pir
f
M
S
LS
Pir
g
M
S
h
M
S
Hp
Hb
Vp
Amyg
i
Hp
Au
Ip
j
SC
Pn
k
Cerebellum
Cb
MVe
Pr
l
Olfactory bulb
m
Hp
Hb
Vp
Amyg


a
70 mM K+
-63.7 mV
20 mV
1 min
Sample collection
Control
70 mM K+
Wash
b
Glutamate
c
GABA
d
Creatine
nmol/min
ns
***
**
##
Control
70 mM K+
wash
Slc6a8+/Y
Slc6a8-/Y
e
Glutamate
f
GABA
g
Creatine
#
###
0 Ca ACSF
0 Ca 70 K+
2.5 Ca 70 K+


a
1
2
3
4
5
6
7
8
9
Wildtype alle
FRT
En2 SA
IRES
LacZ
pA
LoxP
hbacP
neo
pA
FRT
LoxP
LoxP
Agat KO First
b
Creatine
nmol/min
0.20
0.15
0.10
0.05
0.00
***
**
***
###
###
###
##
##
#
Control
70 mM K
Wash
Agat+/+
Agat+/-
Agat-/-
c
Glutamate
nmol/min
0.5
0.4
0.3
0.2
0.1
0.0
ns
ns
***
d
GABA
nmol/min
0.8
0.6
0.4
0.2
0.0
ns
ns
***


a
b
c
100 μM Creatine
Inhibition
No effect
n=16
n=35
d
Control
100 μM Creatine
Wash
-69 mV
20 mV
200 ms
e
f
g
Control
Creatine
Wash
Spike number
inject current (pA)
h
i
j
***
**
*
Rheobase (pA)
Input resistance(MΩ)
Control
Creatine
Wash


a
Slc6a8-HA+
Slc6a8-HA-
Slc6a8-HA+
Slc6a8-HA-
H S1 P1 S2 P2 Sy
1 2 3 4-Sy 5 6
HA
SNAP25
SNAP23
Syp
PSD95
GluN1
Na+-K+ ATPase
VDAC
GAPDH
MBP
b
Slc6a8+/Y
Slc6a8-/Y
Mt
PSD
SV
Sy
Number
(μm2)
c
[14C]-Cr (pmol/mg protein)
***
Ctrl
Uptake
Slc6a8+/Y
Slc6a8-/Y
d
[13C]-Cr (pmol/μg Syp)
-ATP
+ATP